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1. INTRODUCTION 
 
1.1 Papillomaviruses: phylogenesis and taxonomy 
Papillomaviruses (PVs) are DNA viruses infecting a large number of mammals 
including humans and considered to be oncogenic; indeed, they were firstly detected in 
rabbits and cattle and in human skin warts (Shope and Hurst, 1933; Rowson and Mahy, 1967; 
Olson et al., 1951; zur Hausen, 2009). Their tropism is restricted to skin, squamous mucosal 
epithelia of mouth, anus and genital tract and are usually considered to be strictly specie-
specific, although some rare cases of cross infection are known (Campo, 2002). Phylogenetic 
studies strongly suggest linked evolution between PVs and their host specie as a possible 
mechanism defining the evolutionary history of the virus, meaning that major part of 
evolutionary diversification of PVs must have proceeded thrugh molecularly unknown 
mechanisms that restrict PVs to their host species (Bernard, 2013). 
PVs were originally grouped toghether with polyomaviruses in the family of 
“Papovaviridae”, based on shared rare features: both virus groups harbour a double stranded 
circular DNA genome with a size of 5kb for polyomaviruses and 8kb for PVs and have a non-
enveloped icosahedral capside (Bernard, 2013). However, the different structural and 
functional genomic organization of PVs and the unique combination of biological properties 
led the International Committee on Taxonomy of Viruses (ICTV) to classify this group as a 
separate “family”, named Papillomaviridae (De Villiers et al., 2004). 
Many of the known PVs were originally defined using the abbreviation of the name 
referred to the host species followed by a number indicating the “type” (e.g human PV type 
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16 is termed HPV16); however, today the scientific name of the host species is preferred to 
the informal and common one when a new PV is identified (Bernard, 2010).  
The phylogenetic tree of Papillomaviridae family includes 189 “types” forming 70 
species (corresponding to the minor branches) grouped in 30 genera (represented by the major 
branches) (Figure 1) (Bernard, 2010).  
 According to the last official classification, 120 PVs types are isolated from humans, 
64 from mammals, 3 from birds and 2 from reptiles (Bernard, 2010). The classification of 
PVs was originally based on the biological and clinical properties, but taxonomic decisions 
were ultimately based on the phylogenetic tree topology. This new way of classification is 
based on the sequence of L1 gene: a PV is defined as a new “type” when a difference of at 
least 10% is detectable with all the known types, whilst isolates with 2-10% diversity are 
termed as “subtypes” (Bernard, 2013). Several studies suggest that genomic variation at this 
level are extremely rare and probably of little biological and clinical significance, in contrast 
to genomic variation up to 2%, termed as “variants” (Calleja-Macias et al., 2005). The 30 
genera are indicated by Greek letters (alpha, beta, gamma, delta, epsilon and so on) and the 
species by addition of a number. For instance, the HPV16, the causative agent of most women 
cervical cancers, indicates the HPV type 16, belonging (toghether with other types) to the 
alpha papillomavirus genus, species alpha 9 (Bernard, 2013).  
 However, the great diversity among PVs and the putative differences in the 
pathogenetic mechanisms are still object of phylogenetic and biology studies leading to the 
discovery of new animal and human PVs types, so that the phlylogenetic tree of 
Papillomaviridae has to be continuously updated. 
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Figure 1 
Philogenetic tree of the 189 papillomavirus types based on the nucleotide sequence of the L1 gene 
(modified from Bernard et al., 2010). The sequence identities decrease from close to 90% to about 45% in 
intraspecies, interspecies and intergeneric comparison. Alpha and beta genera (red squares) contains most of 
oncogenic HPVs 
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1.2 Genomic Organization of PVs 
   PVs are generally characterized by a proteic icosahedric capside with a 55 nm diameter, 
made of 72 capsomeres, each resulting from the assembling of 5 monomers of L1 structural 
protein. The capside encloses a double-stranded circular DNA genome of approximatively 
8kb, whose structural and functional organization is highly conserved among the different 
PVs. It contains 8 open reading frames (ORFs), all being transcribed from one DNA strand 
only and encoding for a specific mRNA and its relative protein (Fehrmann and Laimins, 
2003). Each of these proteins display a specific function in the life cycle of the virus. The 
HPV16 genome can be shown as the prototype of most of PVs genomes (Figure 2), which is 
organized in 3 functionally different regions:  
1) E (early) region, showing different ORFs which encode for early proteins E1, E2, E4, E5, 
E6, E7, E8. Taken togheter, they consitute the 45% of the whole viral genome. These 
proteins are basically expressed in the early steps of viral cycle, being involved in viral 
replication and gene transcription. They also display transforming properties through 
molecular mechanisms leading to inhibition of cell death and triggering unscheduled cell 
proliferation. 
2) L (late) region, it accounts for 40% of viral genome and is highly conserved. It is   
constituted by 2 ORFs encoding for major and minor capsidic structural proteins, L1 and 
L2, respectively. These proteins are responsible for the evocation of host immune 
response.  
3)   LCR (Long Control Region) also known as NCR (Non Coding Region), representing 7-
10% of viral genome, it does not show any transcriptional activity, but containing the 
replication origins as well as transcriptional enhancer and promoter sequences playing a 
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role in the control of viral replication and transcription. Generally, it is positioned 
between the end of L1 gene and the beginning of E6 ORF.  
  Despite a high degree of conservation in the genome layout, a number of reported PVs 
show a deviating genomic organization, but the core ORFs E1, E2, L1 and L2 are present in 
all papillomaviruses known so far (Bernard 2013). 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 
The genome of HPV16 has a size and gene arrangement typical for most of papillomaviruses. Some few 
types have rearrangement or replacement of E6 and E7 or may lack E5 (modified from Bernard, 2013). 
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1.3 PVs life cycle 
Several studies have shown that DNA of the most prevalent HPVs can be readily 
detected on the healthy skin with no signs of apparent infection (Doorbar, 2005, Boxman et 
al., 2001). Similar findings have been exstensively reported also for animals, suggesting that 
PVs may be ubiquitarious inert hosts of human and animal skin (Antonsson et al., 2000; 
Antonsson et al., 2002). To actively undergo the infectious cycle, PVs particles must have 
access to cells in the basal layer. In this regard, the hair follicles may represent an important 
site of entry (Boxman et al., 2001). It is thought that the initial infection requires a break in 
the stratified epithelium. Such breaks may not be readily apparent, and may occur under 
conditions where the skin is subjected to environments where micro traumas may develop 
(Doorbar, 2005). Indeed, infectious cycle of PVs begins with an injury to the cutaneous or 
mucosal squamous epithelium, exposing the basement membrane and basal cells layer to the 
virus (Doorbar, 2005). The exact mechanism of virust entry in the cells is not fully 
understood, as well as the cell surface receptor allowing its attachment to the cell membrane; 
a possible mechanism proposed is the internalization via endocytosis of clathrin coated 
vescicles, a process requiring several hours (Giroglou et al., 2001; Culp and Christensen, 
2004; Day et al., 2003, Selinka et al., 2002). The viral uncoating is facilitated by the 
disruption of intracapsomeric disulphide bonds in the reducing enviroment of the cells, 
allowing viral DNA to be transported into the nucleus (Li et al., 1998) 
. At the initial stage, the viral genome replicates as an episomal plasmid to low copy 
numbers in proliferative basal epithelial cells. Expression of E1 and E2 genes is essential to 
mantain the viral genome as episome and to facilitate the correct segregation of genomes 
during cell division (Wilson et al. 2002; You et al., 2004). In uninfected epithelia, upon cell 
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division, daughter cells move up to the spinous layer and initiates differentiation. During PVs 
infection, the expression of early genes like E5, E6 and E7, forces a subset of infected cells in 
the spinous layer to aberrantly re-enter the S-phase of cell cycle to enhance viral DNA 
replication, so that the restraint on cell cycle progression is abolished and normal terminal 
differentiation is delayed (Sherman et al., 1997). Indeed, E5, E6 and E7 genes products are 
considered as oncoproteins, since they stimulate cell proliferation and cell survival (Doorbar, 
2005). As cells with amplified viral DNA move to upper epithelial layers, Late genes L1 and 
L2 are expressed immediately after E4, to encode the proteins aimed to encapsidate viral 
DNA (Doorbar et al., 1997). The major capsid protein L1 is expressed after L2; they both 
allow the assembly of infectious particles (Florin et al., 2002). Subsequently, infectious viral 
particles are released from the surface of stratified epithelium within desquamated cells, 
allowing the viral spreading mostly through direct contact (Figure 3). 
Although genome amplification and packaging is necessary for the formation of new 
replicative virions, infection can have different outcomes. Usually, the viral replication is 
slow and PVs infections remain asympthomatic, due to an efficient immune response by the 
host, thus slow subclinical infections appear to be the most common exitus. However, the 
onset of this response may be variable depending on the conditions of the immune system of 
the infected animal: a delay in the development of a response may trigger rapid replication of 
PVs, which in turn increases basal cell replication and terminal differentiation, resulting in the 
development of an exophytic mass known as papilloma or wart (Doorbar, 2005). Usually they 
persist for a relatively short period in terms of weeks (generally in all the species including 
humans), until they regress upon the rescue of immune system functionality, mostly driven by 
lymphocyte infiltration (Nicholls et al., 2001). Following regression, PV DNA is thought to 
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remain in the basal epithelial cells establishing a latent infection, prone to be reactivated when 
levels of immunosurveillance decline (Doorbar, 2005). Whether the immune system remains 
unable to develop an efficient cell mediated response for a prolonged time, a florid infection 
followed by lesion persistence or neoplastic transformation can occurr (Campo, 2002). 
 
 
 
 
 
 
Figure 3 
Schematic representation of papillomavirus life cycle (modified from Doorbar, 2005). Viral genes expression 
profiles are show for each phase of the infectious cycle. 
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1.4 Papillomaviruses and cancer 
PVs are considered to be oncogenic: the first evidences of their carcinogenic potential 
came from experimental observations during the early decades of ‘900 on human and animal 
tumours. However, it was since 1960s that, with the evolution of molecular techniques, there 
was a great acceleration in the discovering of causal association of PVs with different forms 
of cancer so that, today, the carcinogenic role of several PVs is well established in humans 
and animals (see zur Hausen 2009). 
Most of HPVs known so far are classified into two genera: alpha and beta. Among the 
genus alpha HPVs there are cutaneous types inducing benign, non-genital skin warts, and 
mucosal types, divided in two groups: the low-risk (LR) types inducing genital warts and 
laryngeal papillomas and the high-risk (HR) HPVs which are  causative agents of cervical, 
anogenital and oropharyngeal cancers (reviewed in Howley, 2013). HPV16 and HPV18 are 
the most frequently types detected in cervical cancers worldwide, thus the majority of the 
biological studies have been focused on these two types. The oncogenic potential of HR 
HPVs is due to the transforming properties of E6 and E7 viral oncogenes, which are 
invariably highly expressed throughout the development of cervical cancer (see below). 
The beta HPV types were firstly isolated in skin cancer-prone patients suffering from 
an immunity disorder known as Epidermodysplasia verruciformis (EV). These patients suffer 
from persistent HPV infection of the skin causing extensive flat warts, mostly progressing to 
squamous cell carcinoma (SCC) in sun-exposed regions. Immunosuppressed organ transplant 
recipients are also predisposed to beta HPVs-induced skin cancer; additionally, beta HPVs 
types infection is very common in the skin of healthy individuals, suggesting that immune 
system decline and other co-factors such as UV exposure are necessary for development of 
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HPV associated skin cancer. The precise role of beta HPVs in skin cancer is not fully 
understood so far, especially in non EV patients, however a number of studies on the 
transforming properties of beta types E6 and E7 oncogenes confirmed their carcinogenic 
potential (reviewed in Howley and Pfister, 2015). 
Among animal PVs, 13 bovine papillomavirus (BPVs) types have been identified and 
associated to different skin and mucosal cancers in bovids and other species. The most studied 
BPVs types are BPV1 and BPV2 (genus delta) which cause cutaneous fibropapillomas and 
urinary bladder cancer and BPV4 (genus Xi) that induces esophageal cancer in cattle. As for 
the human counterpart, additional co-factor are required for carcinogenesis: the 
immunosuppressive and carcinogenic chemicals contained in the bracken fern are known to 
play a key role in BPVs associated bovine cancer. Although PVs are generally species 
specific, BPV1, 2 and recently 5 and 13 represent an exception, being able to infect buffaloes, 
equines, yaks, tapirs, giraffes, donkeys, bisons and zebras (for review see Bocaneti et al., 
2014). In equids, BPV1 and 2 are known to contribute to the development of a fibroblastic 
dermal tumour termed sarcoid, the most common skin neoplasia in horses worldwide 
(reviewed in Nasir and Brandt, 2013). Differently from HPVs, the main oncogene of BPVs is 
E5 (see below) with a minor role played by E6 and E7 (see Corteggio et al., 2013 for review). 
Fifteen canine PVs (CPVs) have been recognized so far, belonging to different genera. 
Although less clearly established and not extensively deepened through molecular studies, a 
role for CPVs infection has been hypothesized also for oral and skin epithelial benign lesions, 
possibly progressing to malignant cancer in dogs (for review see Rector and Van Ranst 2013 
and Munday and Kiupel 2009). 
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The first evidences of a role for cottontail rabbit PV (CRPV) in the early ‘900 have 
been strenghtened by dozens of studies throughout the decades. CRPV induces cutaneous 
papillomas which in most of the cases progress to invasive SCC without any other known co-
factors. Both E6 and E7 encoded by CRPV display transforming properties (Ganzenmueller et 
al., 2008). 
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1.5 Viral proteins 
As stated before, PVs genome encodes for early and late proteins, differently involved 
the PVs lyfe cycle. Indeed, whilst L1 and L2 are basically structural proteins forming the viral 
capside, early proteins show a wide range of molecular function during the PVs infection.  
 
1.5.1 Early proteins  
Here, a comprehensive overview of early genes functions is reported. As thoroughly 
described below, the E1, E2 and E4 proteins display regulative functions in specific stages of 
the viral lyfe cycle, such as viral transcription and replication or viral particles release, while 
E5, E6 and E7 are considered to be oncogenes for their tranforming activities including the 
impairing of apoptosis and the increasing of cellular proliferation whithin the infected 
epithelia. 
 
E1 proteins 
The E1 has a molecular weight of 68 KDa and is expressed at low levels in PVs 
infected cells. Its main function is to bind the replication origin contained in the LCR and is 
characterized by an ATPase and 3’-5’ helicase activity (Hughes and Romanos, 1993; Seo et 
al., 1993; Yang et al., 1993). 
E1 recognizes and weakly binds to AT rich regions within the replication origins of 
PVs (Frattini and Laimins, 1994; Muller et al., 1997). This binding is stabilized through 
forming a complex with E2 protein (Frattini and Laimins, 1994; Dixon et al., 2000; Lu et al., 
1993). The E1 binding sites (E1BS) are flanked by two E2 binding sites (E2BS) and E2 
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allows the correct positioning on the origin of replication by E1, which in turns forms 
hexamers with high affinity for DNA (Sedman and Stenlund, 1998). 
Additionally, E1 proteins are able to bind the DNA polimerase α of the host cell and to trigger 
the recruitment of protein complexes involved in DNA replication to the viral replication 
origin (Conger et al., 1999; Masterson et al., 1998). 
 
E4 proteins 
Generally, the papillomavirus E4 ORF is contained within the E2 ORF, with the 
primary E4 gene-product being translated from a spliced mRNA that includes the E1 initiation 
codon and adjacent sequences; indeed, the E4 is located centrally within the E2 gene (Wang 
et al., 2011). Although a number of minor E4 transcripts have been reported, the product of 
the most abundant full-lenght mRNA has been most extensively analysed (Chow et al., 
1987; Doorbar et al., 1990; Wang et al., 2011). During the papillomavirus life cycle, the E4 
protein is expressed at the onset of vegetative viral genome amplification as the late stages of 
infection begin. E4 contributes to genome amplification success and virus synthesis, with its 
high level of expression suggesting additional roles in virus release and/or transmission. Thus, 
the E4 protein can serve as a biomarker of active virus infection (Middleton, 2003; Borgogna 
et al., 2012). In some cutaneous lesions, E4 is expressed at higher levels and invariably before 
the virion coat proteins L1 and L2. The E4 proteins of the beta, gamma and mu HPVs 
assemble into distinctive cytoplasmic, and sometimes nuclear, inclusion granules (Laurent et 
al., 1982; Egawa, 1994). The E4 structure and function is affected by cellular kinases (protein 
kinase A, Cyclin-dependent kinase, members of the MAP Kinase family and protein kinase 
C) as the infected cell progresses through the S and G2 cell cycle phases, but also by 
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proteases as the cells undergo through terminal differentiation (Doorbar, 2013). For HPV16, 
these kinases regulate the E4 main function, that is the association with the cellular keratin 
network, and eventually also its cleavage by the protease calpain which allows assembly into 
amyloid-like fibres  (Doorbar, 2013; McIntosh et al., 2008); this reorganisation of the keratin 
network makes it mechanically unstable and thus facilitates the release of viral particles 
(Doorbar et al., 1991).      
Although different in the primary amino acidic sequences, the E4 proteins share a 
recognisable modular organisation and pattern of expression, which may underlie conserved 
functions and regulation. Assembly into higher-order multimers and suppression of cell 
proliferation are common to all E4 proteins known so far. Although not yet formally 
demonstrated, a role in virus release and transmission remains a likely function for E4 (Brown 
and Bryan, 2000; Brown et al., 2006; Bryan and Brown, 2001). 
 
E2 proteins 
The full-lenght E2 protein is an essential regulatory protein encoded by all PVs 
Additionally, all the viruses potentially encode for shorter E2 species (McBride, 2013). E2 are 
DNA binding proteins which specifically recognize and bind to a 12 base pairs (bp) motifs 
located within the LCR. These proteins display multiple functions, mostly associated with 
transcription and replication of viral genome and are mostly expressed during the early and 
intermediate stages of the viral lyfe cycle (McBride, 2013). The E2 proteins are the main 
transcriptional regulators of the PVs, acting by recruiting cellular factors to the viral genome; 
thus E2 may activate or repress transcription depending on the context of these binding 
partners (Choe et al., 1989; McBride, 2013). On the contrary, the shorter E2 isoforms deriving 
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from alternative splicing of the mRNA, invariably act as transcriptional repressors by 
different mechanisms (i.e. dimerization with full-lenght E2 or competition for binding sites) 
(Barsoum et al., 1992; Lim et al., 1998). The fine regulatory function of E2 can be disrupted 
by mutation or integration of the viral genome, leading to alleviation of E2-mediated 
repression and increased expression of E6 and E7 transforming genes of HR PVs (Bernard et 
al., 1989). Low levels of E6 and E7 upon E2 transcriptional repression are essential for 
keeping a non-transformed phenotype in non-productive stages of PVs infection, thus lost of 
E2 by viral genome integration strongly contributes to malignant progression in cervical 
cancer in women (McBride AA, 2013).  
 Nevertheless, the E2 proteins play a key role in the intiation of viral replication by 
loading the E1 helicase onto the replication origin, which contains an E1BS and at least one 
E2 binding sequence (Sanders and Stenlund, 2000; Ustav et al., 1993). E2 is essential for viral 
replication also through displacing nucleosomes from the origin to alleviate transcriptional 
repression (Li and Botchan, 1994). Additionally, viral replication occurr in nuclear foci, and 
the formation of these foci is dependent upon E2 expression (Fradett-Turkotte et al., 2011). 
On the contrary, several alternative shorter E2 isoforms act as inhibitors of viral DNA 
replication as well as transcriptional repressors: this is believed to be important in the 
manteinance phase of replication or for episomal manteinance (Lace et al., 2008). In this 
regard, another important function of E2 is to tether viral genome (through binding E2BS of 
viral DNA) to mitotic chromosomes through protein-protein interaction (through different E2 
protein motifs) in order to facilitate retention, manteinance and partitioning of the virale 
genome (Bastien and McBride., 2000; Kurg et al., 2010).   
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 Several studies suggest additional functions for E2, among these a role in the 
packaging of viral DNA, post-transcriptional RNA processing, regulation of cellular gene 
expression or growth inhibition and apoptosis both in PVs positive and negative cells through 
different mechanisms (Zhao et al, 2000; Johansson et al., 2012; McBride, 2013; Johung et al., 
2007). 
In summary, expression and functional activity of E2 indicates that a PV is 
biologically active within an infected epithelium. 
 
E5 proteins 
 Many but not all the PVs encode E5 proteins, short membrane-associated proteins 
with potent transforming activity but poorly defined roles in productive infection. Deriving 
from a spliced mRNA initiating upstream of the E2 gene, this protein varies from a size of 
approximatively 40 to 85 amino acids being predominantly hydrophobic, clusterd in one or 
more putative transmembrane domains. Despite the globular structure conferred by the 
aminoacidic composition and the very small size, E5 show an energetically favorable shape 
which favours the disposition of side-chain outside the core of the protein, facilitating the 
interaction with a great numbers of cellular targets (DiMaio and Petti, 2013). 
 The most studied E5 are those from BPV1 and HPV16: despite they show minimal 
sequences similarity with each other, they display overlapping transforming activities and 
share molecular targets (DiMaio and Petti, 2013). BPV1 E5 is the prototype of E5 protein 
encoded by the fibropapillomaviruses belonging to the genus delta (van Doorslaer, 2013). It is 
expressed in basal keratinocytes and superficial differentiated keratinocytes of the highly 
proliferative epithelia within bovine skin warts, as well as in the fibroblasts of dermal 
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prominent component of these tumuors (Burnett et al., 1992). Here, as in bovine urinary 
bladder tumours and BPV1 induced equine sarcoid, the main tranforming activity of this E5 is 
linked and dependent by its ability to bind to and activate the plateled-derived growth factor 
beta receptor (PDGFβR); this highly specific interaction takes place in the inner 
intermembranes space, as E5 forms homodimers which can recruit two monomers of 
PDGFβR that in turn may auto-transphosphorylate thus activating a signaling cascade 
resulting in recruitment and activation of cellular singalling proteins and finally mitogenesis 
(for review see Venuti et al., 2011 and Corteggio et al., 2013). Another transforming activity 
of BPV1 E5 is linked to its localization in the membrane of Golgi apparatus, where it binds to 
the subunit c of the vacuolar ATPase, causing the alkalinization and swelling of this and other 
vescicular structures (Goldstain et al., 1992; Tsirimonaki et al., 2006) 
 Additionally, BPV1 E5 contributes to the evasion of immune response by infected 
cells through inhibition of cell surface expression of major histocompatibility complex class I 
(MHCI) antigens, by its transcriptional repression and impairment of intracellular trafficking 
(Ashrafi et al., 2006; Marchetti et al., 2002). 
 HPVs E5 is highly hydrophobic as BPV1 E5, although no sequence homology is 
shared. Not all the HPVs encode E5 and E5 proteins from different HPV types display 
different biological and transforming properties (Bravo and Alonso, 2004). The most potent 
E5 among HPVs is HPV16 E5, which localizes mostly in the endoplasmic reticulum (ER), 
Golgi apparatus (GA), plasma membrane and nuclear envelope (DiMaio and Petti, 2013). 
However, this E5 display a weak transforming activity when compared to BPV1 E5, since it 
is more likely to cooperate with other oncogenes such as E6 and E7 in malignant 
transformation (DiMaio and Petti, 2013); its main oncogenic property is to sustain the 
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activation of  epidermal growth factor receptor (EGFR) pathway through different 
mechanism, for instance by increasing its expression on cell surface or reducing its 
degradation, thus sensitising cells to mitogenic signaling by EGF or stimulating the 
expression or activation of signaling molecules involved in the downstream pathway 
(Tomakidi et al., 2000; Zhang et al., 2005). Additionally, as BPV1 E5, HPV6 and HPV16 E5 
are able to bind the subunit c of the vacuolar ATPase, but the role of this interaction in 
oncogenesis is not yet fully understood (DiMaio and Petti, 2013). Another function shared 
with BPV1 E5 is the impairing of MHC antigens expression on cell surface, acting at different 
levels of their cellular trafficking, mainly through physical binding to MHC molecules and 
cellular chaperones (Ashrafi et al., 2006; DiMaio and Petti, 2013). HPV16 E5 is also able to 
counteract apoptosis through multiple mechanisms involving EGFR pathway, pro-apoptotic 
Bax and Fas proteins and COX-2-PGE-protein kinase A pathway (DiMaio and Petti, 2013).  
Whilst the transforming activity of HPVs E5 has been clarified, the role of this 
oncogene in viral cycle is not fully clear. E5 mRNA is expressed in the suprabasal 
differentiating cells of HPV-infected epithelia, where it is suggested to contribute to enabling 
these cells to retain their proliferative capacity and perturb keratinocytes differentiation thus 
favouring viral DNA replication (Longworth and Laimins, 2004). 
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E6 proteins 
 All papillomaviruses encode an E6 ORF, positioned immediately downstream of the 
LCR. E6 proteins are approximatively 150 amino acids long and show a conserved structure: 
there are two CX2C-X29-CX2C zinc-like fingers linked by a sequence of 36 aminoacids and 
flanked by short C-terminal and N terminal domains of variable length (Cole and Danos, 
1987). E6 is expressed at low levels and is located in the nucleus (Lowy and Howley, 2001; 
Lipari et al., 2001). No enzymatic activity has been identified for E6 and most of E6 functions 
are thought to be mediated by protein-protein interactions (Howie et al., 2009) (Figure 4). 
The first partner identified to interact with E6 was the E6 associated protein (E6AP), an E3 
ubiquitin ligase, involved in the pathway targeting the proteins to proteasomal degradation 
(Scheffner et al., 1993). The E6AP binds both to E6 and E6 bound proteins, thus targeting the 
partners in the complex to proteasome mediated degradation (Scheffner et al., 1993). Despite 
a large number of studies, the exact residues of E6 binding to E6AP have not yet fully 
identified, while the motif on E6AP that interacts with E6 has been characterized and is 
referred to as an LXXLL motif (Nomine et al., 2006); this motif is present also in other 
proteins able to bind E6, among these paxillin. The ability of E6 to bind this motif is 
conserved among a large number of PVs, including animal PVs such as BPV1 (Tong and 
Howley, 1997).  
 HR HPVs E6 is able to bind to another class of cellular partners known as PDZ 
proteins: the name of these protein comes from the PDZ domain, a 90 amino acids stretch 
found in a variety of proteins sharing this domain, among these hDlg proteins, MAG 1-3, 
MUPP1, PTPN3 (Kiyono et al., 1997; Thomas et al, 2001; Lee et al., 2000; Spanos et al., 
2008). This binding is mediated by a motif designated as S/TXV domain on the E6 C-termini. 
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The PDZ proteins are targeted to proteasomal degradation in case of concurrent binding of E6 
to E6AP, although some other ubiquitin ligases have been implicated (Sterlinko et al., 2004). 
 Other proteins such as p53 and p300 have been reported to bind E6 despite lacking an 
LXXLL or a PDZ domain. The may bind E6 through motifs not yet identified or indirectly 
through binding to E6AP or other E6 associated proteins (Howie et al., 2009). 
 The most studied interacting protein of E6 is the tumor suppressor p53, a transcription 
factor coordinating the cellular response to genotoxic or citotoxic stress. Normally present at 
low levels and functionally inactive, cellular damage triggers an increase in p53 protein level 
and an activation via post-translational modifications. Once activated, p53 can direct the 
cellular response towards DNA repair, cell cycle arrest and/or programmed cell death 
(apoptosis), depending on the type and the extent of the damage (Murray-Zmijevski et al., 
2008). PVs have evolved a number of mechanisms to block p53 function in infected cells, 
mainly through E6 oncoproteins (Howie et al., 2009). Indeed, the principle mechanism of p53 
inactivation, typical of HR HPVs, is the binding to E6AP through the mediation of E6, which 
leads p53 to proteasomal degradation (Scheffner et al., 1990); normally, E6AP does not bind 
to p53, but when E6 binds to E6AP, this becomes able to bind and ubiquitinate p53 
(Huibregtse et al., 1993). Both HR and LR HPVs E6 binds to p53; however, while both HR 
and LR bind to p53 C-termini, only HR E6 bind to the core region, and this is known to be 
necessary for p53 protein degradation (Crook et al., 1991; Li and Coffino, 1996). Thus, LR 
HPVs E6 have evolved different strategies to inactivate p53, including inhibition of its 
binding to DNA, aberrant localization and post-translational modifications. Indeed, the 
binding of these E6 to p53 may induce p53 conformational changes, disrupting the interaction 
with sequence-specific DNA motifs, or mask the nuclear localization sequences (NLS) at the 
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C-termini leading to cytoplasmic accumulation of p53 (Howie et al., 2009). Another known 
mechanism involves the binding of E6 to p300: normally, p53 is acetylated by p300 following 
to DNA damage, thus enhancing its transcriptional activity.  When bound to E6, p300 is not 
able to acetylate and activate p53, resulting in lower p53 function (Zimmermann et al., 2000). 
Several other studies report a role for E6 in interacting, degrading and abrogating the function 
of histone acetyltranferase hADA3, which leads to the loss of p53 transactivation of 
downstream genes (Kumar et al., 2002). 
 One of the main consequences of E6 degrading or blocking p53 function is to inhibit 
apoptotic signaling that would otherwise eliminate the infected cells, as several pro-apoptotic 
genes are among the p53 transcriptional targets. Interstingly, E6 is known to interfere with 
both intrinsic and extrinsic pathways of apoptosis (Howie et al., 2009). E6 has been shown to 
inhibit the extrinsic pathway acting at each level of the early stages, for instance by binding 
and triggering degradation of death receptors, adaptor proteins or to Caspase 8 (Filippova et 
al., 2002; Filippova et al., 2004; Garnet et al., 2006). 
 Other cellular stresses such as DNA damage or oxidative stress activate a number of 
pathways that converge on the mithocondria, which act as a hub to sense the balance of pro- 
and anti-apoptotic signals. When the cells senses intrinsic stresses, the balance is upset in 
favour of pro-apoptotic proteins, allowing the formation of pores in the mithocondrial 
membranes comprised of Bax and Bak proteins, and the subsequent release of proteins 
including the cytochrome c. These proteins form the apoptosome, a signaling complex that 
results in cleavage of caspases, and ultimately cell death (Howie et al., 2009). Other than 
inhibiting the expression of pro-apoptotic p53-dependent genes including Bax through 
impairing p53 protein, the E6 from HPVs have been found to interact with Bak and induce its 
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proteasomal dependent degradation, thus blocking the intrinsic apoptotic pathway (Thomas 
and Banks, 1998; Underbrink et al., 2008). 
 Another important oncogenic function of E6 is the disruption of cell adhesion, polarity 
and epithelial differentiation, in order to allow proliferation of differentiated cells and 
inhibition of terminal differentiation to support viral replication. For instance, E6 from 
different human and animal PVs, binds to paxillin, a focal adhesion molecule involved in 
tethering the cellular cytoskeleton to the ECM and transmit signals along the actin network 
from ECM to the nucleus (Degenhardt and Silverstein, 2001; Tong and Howley, 1997). This 
binding results in the disruption of actin fibers and failure in mantaining the cell structure. 
Additionally, E6 binds to and inhibits proteins involved in epithelial tight junctions and may 
regulate cell proliferation, such as hDlg, MAG 1-3, MUPP1, PTPN3, thus impairing their 
function as tumor suppressors (Howie et al., 2009). 
 Other functions by E6 are known to be very important in the transforming processes 
leading to malignant transformation induced by PVs, among these the induction of the 
catalytic subunit of human telomerase hTERT, modulation of G-protein signaling and 
immune recognition, interaction with proteins involved in mantaining chromosomal stability, 
thus leading to accelerated progression to carcinogenesis (Klingelhutz et al., 1996; Howie et 
al., 2009). 
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Figure 4 
Binding partners of E6. E6 alters numerous cellular pathways mainly through protein-protein interactions 
(modified from Howie et al., 2009). 
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E7 proteins 
 The E7 proteins are small polypeptides of approximatively 100 amino acids. The 
amino-terminus of PVs E7 shares high homology with conserved region 1 and 2 (CR1 and 
CR2) of adenovirus EA1 and with the large tumor antigen of simian virus SV40 and these 
regions are necessary for the transforming properties of the three viruses (Figge et al, 1998; 
Phelps et al., 1988; Vousden et al., 1989). A conserved Leu-X-Cys-X-Glu (LXCXE) motif in 
the CR2 domain is necessary and sufficient for the binding to cellular retinoblastoma tumour 
suppressor protein (pRb) (Munger et al., 1989). Additionally, the C-termini of E7 contains a 
zinc-binding domain that is composed of two Cys-X-X-Cys motifs and function as a 
dimerization domain, although there are no definitive evidence for E7 acting as a dimer in 
vivo (Ohlenschlager et al., 2006). HPV16 E7 is located in the cytoplasm and, to a lesser 
extent, in the nucleus, despite no NLS is present in the amino acidic sequence (Ressler et al., 
2007; Smith-McCune et al., 1999). Recent studies suggest that E7 can shuttle between 
cytoplasm and nucleus due to a nuclear export signal (Knapp et al., 2008). As for E6, E7 lacks 
intrinsic enzymatic activity and is widely accepted that its functions are linked to the ability to 
associate with and subvert the normal activity of cellular proteins (Figure 5) (McLaughlin 
and Munger, 2009). 
 HPVs E7 proteins associate with pRb and the related pocket proteins p107 and p130 
through the LXCXE motif (Dyson et al., 1992). These proteins are involved in the regulation 
of the G1/S entry and progression by modulating the transcriptional activities of E2F 
transcription factors. Normally, pRb is complexed with E2F forming a transcriptional 
repressor acting specifically in G1. In late G1, cyclin dependent kinases (cdks) phosphorylate 
pRb leading to the disruption of pRb/E2F complex. Dissociated E2F acts as a transcriptional 
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activator of several genes necessary for entry and progression in S-phase (Frolov et al., 2004). 
The E7 binds to pRb preferentially in the G1 specific pRb/E2F repressor complexes, causing 
its disruption and uncontrolled G1 exit and S-phase entry (Dyson et al., 1992).  The 
destabilization of pRb is mediated through inducing proteasomal degradation via association 
with cullin 2 ubiquitin ligase complex by E7 (Huh et al., 2007). The LR HPVs E7 binds to 
pRb with lower efficiency due to a single aminoacidic substitution (Gly22 vs Asp21) (Gage et 
al., 1990). The transforming ability of E7 correlates directly with pRb binding efficiency and 
thus with the specific aminoacid in that position (Heck et al., 1992; Sang et al., 1992). 
However, beta cutaneous HPVs conserve Asp21 and efficiently bind to pRb, but this does not 
associate with their classification as HR in vivo and does not necessary predict transforming 
potential in vitro (Ciccolini et al., 1994).  
 As a consequence of the enhanced E2F activity, its downstream genes involved in S-
phase entry and progression are upregulated in E7 expressing cells, among these Cycline A 
and E which are the catalytic subunit of cdk2 (Zerfass et al., 1995). E7 dysregulates G1/S cell 
checkpoint by additional mechanisms. HPV16 E7 interacts with and abrogate the growth-
inhibitory activities of p21 and p27 which are normally induced by antiproliferative signals 
and directly binds to cdk2/cyclins complexes resulting in enhanced cdk2 activity (Funk et al., 
1997; Zerfass-Thome et al., 1996). 
 Additionally, E7 is known to impair anoikisis, a form of apoptosis triggered when 
cells enter the S-phase despite not attached to the ECM in the basal layer, the only site within 
epithelium where cells are committed to proliferate (Frisch et al., 2001). The resistance to 
anoikisis is a hallmark of cancer and is tightly mediated also by the Rb associated protein 
p600. HR and LR HPVs, as well as BPV1 E7, bind to p600, thus dysregulating anoikisis and 
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contributing to viral transformation (DeMasi et al., 2007; Huh et al., 2005; Corteggio et al., 
2011). 
Further additional mechanism of HPVs E7 mediated transformation include its ability 
to perturb the epigenetic program of host cells trough interaction with members of the 
polycomb group transcription factor complexes, to impair the TGFβ mediated growth 
inhibition, to interfere with interferon and insulin-like growth factor signaling and favour the 
chromosomal instability (McLaughlin and Munger, 2009).  
Among animal PVs, BPV1 E7 is considered as a weak transforming gene, as it 
synergies with E5 in cell transformation during cancer development. E7 expression 
correlates in vivo with the over-expression of β1-integrin, which plays a role in the regulation 
of keratinocytes proliferation and differentiation; additionally, BPV1 E7 is involved in cell-
mediated immune responses leading to tumour rejection and invasion process by upregulation 
of Matrix metalloproteinase1 (MMP-1) expression (for review of BPVs E7 see Corteggio et 
al., 2013). BPV4 E7, unlike BPV1 E7, possesses the canonical Cys-X-X-Cys motif and the 
pRb interaction domain, that is crucial for its transforming ability (Pennie et al., 1993). Cotton 
tail rabbit PV (CRPV) E7 binds and degrade pRb and show high transforming activity, since 
it is able to immortilize rabbit primary cells when expressed individually (Ganzenmueller et 
al., 2008). 
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Figure 5 
Schematic representation of HPV E7 and affected cellular processes (modified from McLaughlin and 
Murgen, 2009). 
 
 
 
 
 
 
 
 
 
32 
 
1.5.2 Late proteins  
PVs Late genes encodes for the capsidic proteins L1 and L2. L1 is the major capsidic 
protein with a molecular weight of 55-60 KDa, whlist L2 is the minor protein with a size of 
70 KDa. The viral capside is composed of 72 capsomeres. Each capsomer is a pentamer 
composed of 360 molecules of L1 proteins (Figure 6) and 12 up to 36 molecolules of L2 
protein (Modis et al., 2002). Late genes transcription is strictly dependent upon the stage of 
keratinocytes differentiation (Doorbar, 2005). L1 is characterised also by some post-
translational modifications such as phosphorylation and glycosilation. L1 is necessary for the 
virions assembly and production of complete infectious particles and is highly antigenic, 
whilst L2 plays both structural and regulatory functions: it accumulates nuclear structures 
known as PML bodies during virus assembly and recruits L1 to these domains (Becker et al., 
2004). It has been suggested that PML bodies may be the sites of papillomavirus DNA 
replication and that capsid proteins accumulate at these sites to facilitate packaging (Swindle 
et al., 1999) 
 
 
 
 
 
 
 
 
 
 
 
33 
 
 
 
Figure 6 
L1 is the major structural proteins involved in the assembly of PVs ichosaedric capside 
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1.6 Papillomaviruses in felids 
   It is worthwhile noting that PV-induced diseases in felids have been much less studied 
when compared to other species. Indeed, only in recent years several studies have been 
conducted to detect, classify and find possible associations of PVs infection with epithelial 
cancer in domestic as well as in exotic felids.  
Among the PVs identified in felids, major efforts have been conducted to study the 
PVs of the domestic cat (Felis catus). Indeed, several PV genomes have been isolated from 
different species of the family Felidae, among these Lynx rufus (LrPV1), Pantera leo (PlPV1), 
Puma concolor (PcPV) and Uncia uncia (UuPV1) (Sundberg et al., 2000;), but the entire 
genomic DNA sequence has thus far been determined only for Felis catus Papillomavirus type 
1, 2 (FcaPV1/2), and very recently for types 3 and 4 (FcaPV3/4) (Tachezy et al., 2002; Lange 
et al., 2009; Munday et al., 2013; Dunowska et al., 2014).  
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Felis catus papillomavirus type 1 (FcaPV1) 
The FcaPV1 was originally isolated by from cutaneous hyperkeratotic lesions from an 
old domestic short-haired Persian cat, affected with an inherited form of immunodeficiency  
(Chediak–Higashi syndrome) (Tachezy et al., 2002). The cat had received longterm 
corticosteroid therapy, which might have contributed to the immune suppression (Carney et 
al., 1990), strenghtening the hypothesis of impaired immune system as a co-factor also in 
feline PVs associated skin lesions. 
The complete genome contains 8300 bp (substantially larger than that of most of PVs) 
and has a GC-content of 46%. FcaPV1 contains seven major ORFs coding for five early 
proteins E1, E2, E4, E6, and E7 and two late proteins L1 and L2 (Figure 7).  
The E6 contains four C-X-X-C motifs, whereas the E7 contains two such motifs. The E7 also 
contains the conserved pRb binding domain (DLRCYEQMPGEEE). The ATP-binding site of 
the ATP-dependent helicases (GPPNTGKS) is conserved in the carboxy-terminal part of E1. 
The E2 contains a leucine zipper domain (L-X6-L-X6-L-X6-L). The E4 ORF is completely 
contained within the E2 gene. Typically, it does not contain a start codon. The peculiar high 
proline content is conserved in E4 ORF of FcaPV1. 
Both L1 and L2 have a nuclear localization signal at the 3’ ends. In FcaPV1, the LCR 
(or upstream regulative region URR) between the stop codon of L1 and the first ATG in E6 is 
only 384 bp long. PVs usually contain an E1-recognition site situated in the middle of two 
E2BS. The E1-recognition site (TGATTGTTGTTAACAAC) is present and three typical 
palindromic E2BS with the sequence ACCG-N4-CGGT, plus an additional degenerate one 
(believed to be functionally important) were identified. The LCR also contains at its 5’ end 
the cis elements necessary for the processing of the L1 and L2 capsid mRNA transcripts. The 
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FcaPV1 genome contains a noncoding region (NCR2) of 1.3 kb between the end of E2 and 
the beginning of L2. No E5 or E5-like protein could be identified in this region, and, in 
contrast to the noncoding region between L1 and E6, there are no E2BS and no clusters of 
regulatory or promotor elements are identifiable. It is possible that this region comes from an 
early integration event with a piece of DNA of unknown function and origin.  
FcaPV1 shows the highest percentage of similarity to Canine PV1 and is clusterd in 
lambda genus. Despite this virus has been firstly reported on skin lesions, it has rarely been 
detected subsequently and recent work suggest FcaPV1 as possibly involved in the 
pathogenesis of feline oral papillomas (Munday and French, 2015); thus, this virus appears to 
be an uncommon cause of skin disease in cats. 
 
 
 
 
Figure 7 
Linear representation of the ORFs of FcaPV1 genome. E6 and E7 putative transforming genes highlighted in 
red (modified from Tachezy et al., 2002) 
 
 
37 
 
Fcatus papillomavirus type 2 (FcaPV2) 
 FcaPV2 was identified by Lange et al. in 2009 and initially named as Felis domesticus 
papillomavirus type 2 (FdPV2). The entire viral genome was amplified from 3 Bowenoid in 
situ carcinomas (BISCs) of 3 different cats by rolling circle amplification (RCA) and 
subsequently sequenced and cloned (Lange et al., 2009). 
FcaPV2 genome consists of 7899 bp with a GC content of 53%. Open reading frame 
analysis reveals the presence of six ORFs encoding the E1, E2, L2, L1, E6 and E7 proteins, 
(Figure 8). The analysis of their putative amino acids sequences reveals the typical features of 
PVs proteins: an ATP dependent helicase motif (GPPNTGKS) is identifiable in E1, two 
putative metal-binding motifs (CX2CX29CX2C) in E6, one such motif and one pRb-binding 
domain (LXCXE) in E7 (Munger et al., 2004; Wilson et al., 2002). The deduced amino acid 
sequences of both structural proteins L1 and L2 were predicted to harbour a basic tail at their 
C-termini. Furthermore, a 615 bp long LCR between the stop-codon of the L1 gene and the 
start-codon of the E6 gene is present. Eight consensus sequences for E2 binding 
(ACCN6GGT) (Androphy et al., 1987) were identified, five of which located in the LCR and 
three within the putative E1 ORF. A putative origin of DNA replication, consisting of two E2-
binding regions flanking an A/T-rich region, is also identifiable within the LCR, as well as a 
polyadenylation consensus sequence (AATAAA) at the 5’ end of the L2 ORF for processing 
the early protein pre-mRNA. Thus, all important elements of a typical papillomavirus genome 
are detectable.  
Phylogenetic analysis revealed that less than 60% of sequence homology is shared 
with the closest related PVs, suggesting that this viruses is the prototype of a new genus. 
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Indeed, in the last revision of PVs taxonomy it was designed as the first member of the new 
genus of dyotheta-PVs (Bernardt et al., 2010). 
FcaPV2 is the PV most frequently associated with feline non-melanoma skin cancer. 
Its frequent detection in feline viral plaques, BISCs and SCCs allowed to hypothesize a role 
for this virus in the pathogenesis of these tumours. However, the virus is widespread and 
often amplified also from clinically healhy skin, suggesting that other co-factors are necessary 
for neoplastic transformation of the infected epithelia (Thomson et al., 2015). Most 
importantly, in all the studies published so far, only a frequent and specific association of 
viral DNA with skin lesions is reported. As for other animal and human PVs, the presence of 
a PV DNA does not prove its involvment in the carcinogenesis, since the virus may be 
considered a simple bystander or displaying a latent infection (Antonsson et al., 2000; 
Antonsson et al., 2002). Thus, a causative role for FcaPV2 in skin carcinogenesis is not yet 
proven. Different approaches should be needed to demonstrate this pathogenetic hypothesis. 
The first evidence may come from in vivo studies demonstrating the biological activity of the 
virus within the lesions. As stated before, only an association of viral DNA with the lesions 
has been reported, but no viral genes expression has been never demonstrated. Furthermore, 
while hundreds of in vitro studies have extensively demonstrated the transforming activity of 
BPVs and HPVs, functional studies focussed on the putative oncogenic properties of FcaPV2 
are completely lacking. Hence the necessity of these new approaches to demonstrate a causal 
role of this virus in the pathogenesis of feline non-melanoma skin cancer, which is the main 
aim of this experimental work. 
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Figure 8 
Schematic representation of the FcaPV2 genome and ORFs. Putative oncogenes E6E7 are highlighted in red 
(modified from Lange et al., 2009). 
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Felis catus papillomavirus type 3 (FcaPV3) 
 Several works report an association of BISCs with a short sequence of PV DNA not 
overlapping with FcaPV2 designated as FdPV-MY2 (Munday et al., 2011; O’Neill et al., 
2011). Recently, the complete genome of this new PVcontaining the FdPV-MY2 sequence 
was amplified from a cat with multiple BISCs and it was designated as FcaPV3 (Munday et 
al., 2013). 
The complete genome counts 7583 bp with a GC content of 46.7%. Differently from 
FcaPV1 and 2, FcaPV3 genome was predicted to encode for six early proteins E1, E2, E4, E5, 
E6, and E7 in addition to the two late proteins L1 and L2 (Figure 9). The E6 protein of 
FcaPV3 contains two conserved zinc-binding domains (CXXC-X29-CXXC), which are 
separated by 36 amino acids. The E7 protein show a single zinc-binding domain but, notably, 
it lacks the pRb binding site (LXCXE). The predicted E1 protein of FcaPV3 contains two 
helicase domains. The C-terminal helicase domain contains the conserved ATP-binding site 
GPPDTGKS and the origin of replication binding domain. The FcaPV3 E1 also contains the 
Cyclin A interaction motifs (RXL), whose function in binding to cyclin/cyclin-dependent 
kinase complexes has been shown to be important for initiation of other papillomaviruses 
replication (Ma et al., 1999). A viral DNA binding domain and the N-terminal transactivation 
domains were identified within E2 gene. The FcaPV3 genome was predicted to encode a 218 
aa protein downstream of E2 that partially overlaps L2. Based on the position of this predicted 
ORF within the E2-L2 region, it was annotated as ORF E5 (Bravo and Alonso, 2004). The 
putative ORF E5 of FcaPV3 shared 51.3% and 49.2% identity at the nucleotide level with the 
E5 of rabbit oral papillomavirus and Canine PV2. The E4 ORF was identified within the ORF 
E2, but in a different translation frame. It has high proline content (15.2%) as reported for 
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other PVs (Van Doorslaer et al., 2007). The LCR comprises 408 bp between L1 and E6. As 
expected, it contains regulatory sequences, including three polyadenylation sites and other 
motifs that have been shown to be necessary for the processing of the L1 and L2 mRNA 
(Birnstiel et al., 1985). An E1BS was present, althought slightly different from the one 
described for other papillomaviruses (Chen and Stenlund, 1998; Holt and Wilson, 1995). 
Three putative E2BS with a consensus sequence ACCN6GGT (Androphy et al., 1987) were 
identified flanking on either side the E1BS, as typical for the papillomavirus origin of 
replication (Stenlund, 2007). Unexpectedly, an additional ORF (nt 7244–7492) was predicted 
within the LCR region of FcaPV3. No ORF has previously been described in this position of a 
PV genome and it is unknown whether or not this ORF is expressed during the life cycle of 
FcaPV3.  
 FcaPV3 forms a well-supported clade with CPV-2 and CPV-7, and is classified as a 
tau-papillomavirus (Munday et al., 2013). 
 
Figure 9 
Schematic representation of the FcaPV3 genome. E5, E6 and E7 (highlighted in red) are putative transforming 
proteins (modified from Munday et al., 2013) 
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Felis catus papillomavirus type 4 (FcaPV4) 
The complete genome of FcaPV4 comprised 7,616 bp with a GC content of 48.8 %.  
As FcaPV3, FcaPV4 genome was predicted to contain eight ORFs coding for E1, E2, E4, E5, 
E6, E7, L1 and L2 (Figure 10) (Munday et al., 2014). The putative E6 protein of FcaPV4 was 
predicted to contain two conserved zinc-binding domains (CXXC-X29-CXXC), but lacked a 
PDZ-binding motif (ETQL) in its C-terminus. Similarly to FcaPV3, FcaPV4 E7 protein 
contains a single zinc-binding domain, but not the pRb protein-binding site (LXCXE). The 
predicted E1 contained two helicase domains and the conserved ATP-binding site 
GPPDTGKS and the origin of replication-binding domain were identified within the C-
terminal one. The FcaPV4 E1 was also predicted to contain four Cyclin A interaction motifs 
(RXL) at positions 124, 194, 287 and 592. The conserved viral DNA-binding domain and the 
N-terminal transactivation domain were also identified within the E2 included. The E4 ORF 
was identified in a different translation frame within the E2 ORF. It had high proline content 
(16.5%) as reported for other PVs (Van Doorslaer., 2007) and a predicted signal peptide in the 
N-terminus. The LCR comprised 429 bp between L1 and E6. The FcaPV4 LCR was predicted 
to contain all the expected regulatory sequences, considered as important for the processing of 
eukaryotic mRNAs, although the distances between these elements in FcaPV4 genome are 
longer than those described for other eukaryotic genes (Birnstiel et al., 1985). A palindromic 
(50-ATTGTTXXXAACAAT-30) E1BS (Chen and Stenlund., 1997) and four putative E2BS 
with a consensus sequence ACCN6GGT (Androphy et al., 1987) were predicted in the 
FcaPV4 genome at the relative positions of E1BS and E2BS, with E1BS flanked on either 
side by the E2BS, typical for the papillomavirus origin of replication (Stenlund et al., 2007). 
Among the PVs known so far, FcaPV4 was most similar to FcaPV3; based on the actual 
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classification criteria, FcaPV3 and FcaPV4 should be classified as two species within tau-PVs 
(Munday et al., 2014).  
 While short sections of this virus have previously been identified in cutaneous SCCs 
(Feline papillomavirus MY03 sequence, GenBank: HM802139.1, Munday JS, unpublished 
data), the virus was cloned and sequenced from the oral cavity of a cat with ulcerative 
gingivitis (Munday et al., 2014). 
Thus, the role of this virus in the development of diseases in domestic cats remains uncertain. 
 
 
 
 
Figure 10 
Schematic genomic organization of FcaPV4. E6 and E7 ORFs encoding for putative oncogenes are highlighted 
in red (modified from Dunowska and Munday, 2014) 
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1.6.1 Cutaneous lesions associated with papillomaviruses 
in the domestic cat (Felis catus) 
 
Cutaneous Papillomas 
Differently from other domestic species, PVs associated cutaneous papillomas are rare 
in the domestic cat. Only two cases have been reported in the literature, one arising on the 
eyelid on the site of a previous surgery, the other one on the nasal planum (Carpenter et al., 
1992; Munday et al., 2007). Microscopically, both papillomas consisted of thickened, folded 
epidermis that contained prominent viral cytopathology. PVs infection was detected by non 
type-specific immunohistochemistry (IHC) in the former case, by PCR in the latter one, where 
HPV9 DNA was detected (Carpenter et al., 1992; Munday et al., 2007). Since PVs are usually 
specie specific and the presence of viral DNA does not necessary mean that the virus is 
biologically active, this apparent cross-infection cannot be considered as a causal factor in the 
development of the lesion and a contamination by contact with human skin cannot be ruled 
out. 
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Viral plaques 
 
Viral plaques are considered to be uncommon in cats, although lesions that remain 
small might be unnoticed. Plaques typically present as multiple, non-painful, non-pruritic, 
ovoid, slightlyraised, <8 mm diameter lesions. They can be pigmented or non-pigmented and 
are often covered with a keratin crust (Figure 11). No area of the body appears to be 
predisposed to development of these plaques (Wilhelm et al., 2006). Microscopically, they 
show a sharply demarcated focus of mildly thickened epidermis containing prominent viral 
cytopathology, but they do not exhibit significant cell dysplasia. The epidemiology and 
pathogenesis of viral plaques in cats is unclear. PVs infection has been detected using 
different approaches in a series of studies (Wilhelm et al., 2006). FcaPV2 is the most common 
virus associated with viral plaques, whilst FcaPV1 has been very rarely detected, suggesting 
that the former PV might be the main cause of these lesions in domestic cats (Tachezy et al., 
2002; Terai and Burk, 2002; Munday and Peters-Kennedy, 2010). FcaPV2 is highly diffused 
and viral DNA is often amplified from the skin of clinically normal domestic cats, suggesting 
that subclinical infection is common in cats (Munday and Witham, 2010). Therefore, since 
FcaPV2 infection is common but viral plaques are rare, the disease is likely to be 
multifactorial. Viral plaques were initially reported in immunosuppressed cats (Carney et 
al.,1990; Egberink et al., 1992) and, although viral plaques have subsequently been reported 
in seemingly immunocompetent cats (Wilhelm et al., 2006), a delayed or impaired cell-
mediated immune response to FcaPV2 could play a role in disease development. The 
biological behaviour of viral plaques is variable, with some plaques remaining small before 
resolving spontaneously, while others progress to BISCs (Wilhelm et al., 2006).  
 
46 
 
 
 
Figure 11 
Feline viral plaque. European cat affected with a viral plaque appearing as a small crusted lesion on the left 
eyelid (black arrow), Conceicao et al., 2007, available at: 
<http://www.scielo.br/scielo.php?script=sci_arttext&pid=S010209352007000300039&lng=en&nrm=iso>.ISSN
01020935.  http://dx.doi.org/10.1590/S0102-093520070003000). 
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Bowenoid in situ squamous cell carcinomas (BISCs) 
BISCs are rare lesions that tend to affect middle-aged to older cats (Miller et al., 1992; 
Baer and Helton, 1993). They usually present as multiple crusting or ulcerated plaques, 
although they may rarely appear as a single lesion. Several authors observed that hairless 
breeds are predisposed to BISCs and lesions are more severe in these breeds (Figure 12). 
Despite BISCs can develop also in haired and heavily pigmented skin (Baer and Helton, 
1993), a role for ultraviolet (UV) light can not be ruled out, since some UV exposed sites 
suche as face, neck and limbs are possibly predisposed (Wilhelm et al., 2006). BISCs are 
often larger than viral plaques, and histopathological analysis reveals well-demarcated foci 
containing epidermal thickening and dysplasia within all levels of the epidermis and 
extending into hair follicles, but remaining confined by the basement membrane. The 
dysplastic cells can have elongated nuclei that tend to be orientated in one direction (the so 
called ‘windblown’ appearance; Gross et al., 2005). PVs infection in BISCs was initially 
highlighted through different techniques such as cytopathology or IHC with variable success 
(LeClerc and Haines, 1997; Gill et al., 2008). However, the improving of high specific 
molecular assays led to a marked increasing of type-specific PV DNA detection in feline 
BISCs (Nespeca et al., 2006; Munday et al., 2007; Munday et al., 2008; Munday et al., 2011). 
From this studies, a frequent and clearly specific association of FcaPV2 DNA is evident; as a 
matter of fact, in 2009, DNA extracted from a BISC was used to determine the complete 
genome of FcaPV2 (Lange et al., 2009). Despite FcaPV2 is the PV that is most frequently 
detected in feline BISCs, some feline BISCs contain other PV types, including human PVs 
(Munday et al., 2007; O’Neill et al., 2011) and the novel PV designated as FcaPV3 (Munday 
et al., 2013). Thus, viral plaques and BISCs share some histological features and both are 
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likely to be caused predominantly by FcaPV2. However, it is currently unknown whether all 
BISCs develop as progressions from viral plaques or whether BISCs can develop de novo. 
The clinical behaviour of BISCs is highly variable, but in many cases a rapid progression with 
the development of numerous large additional lesions can be observed. Additionally, BISCs 
also develop an invasive phenotype and progress to SCC (Baer and Helton, 1993) and a 
prompt removal of any lesions that show rapid progression or the development of an invasive 
phenotype may be necessary (Scott et al., 2001). Surgical excision in not curative, since 
additional BISC lesions often develop in the same cat (Baer and Helton, 1993). Several 
therapies have been proposed for BISCs, such as the treatment with imiquimod cream in one 
published case series, however this therapy was not succesfull (Gill et al., 2008). Although 
several studies report that suppression of cats suffering from BISCs is uncommon (Baer and 
Helton, 1993; Scott et al., 2001; Gill et al., 2008), BISCs can lead to the consideration of 
euthanasia if extensive areas of the skin are affected. 
 
 
 
Figure 12 
European cat affected with multifocal BISC (white arrows) 
(https://www.vetstream.com/felis/Content/Disease/dis60148.asp). 
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Feline cutaneous squamous cell carcinomas (SCCs) 
Cutaneous SCCs are very frequent in cats, most commonly developing on the nasal 
planum, pinnae and eyelids of cats. Based on these anatomical sites, a role for chronic solar 
exposure has been hypothesized; additionally, white-haired cats have 13.4 times risk of 
developing SCC than other colored cats and generally they arise in non-haired, non-
pigmented areas of the body, strenghtening the hypothesis of a key role for UV light 
(Thomson, 2007). Usually, SCCs affect old animals, with a mean age of 12 years (Vail et al., 
1998; Ruslander et al., 1997; Dorn et al., 1971). These tumors are generally locally invasive 
resulting in destruction of underlying tissue, over a long period of time from months to years; 
although slow to metastasize, several cases of more aggressive lesions with highly and rapid 
metastasizing phenotype have been reported (Ravens et al., 2013; Thomson, 2007). 
Metastases to local lymph nodes and lungs can occur in advanced or poorly differentiated 
lesions (Thomson, 2007). 
Macroscopically, feline SCCs appear as flat, ulcerated masses (Figure 13), whilst at 
microscopy analysis they show classical PVs associated cytopathology including cells with 
expanded greyish blue, slightly granular cytoplasm, cells with dark shrunken nuclei 
surrounded by a clear cytoplasmic halo (koilocytes) and clumping of keratohyaline granules 
(Munday, 2013).  This histopathological pattern and the observation that some feline 
cutaneous SCCs evolve from PV-induced BISCs strongly suggest that PVs infection may 
have a causal role in the development of these tumours. Most importantly, PVs DNA has been 
detected in SCCs (Nespeca et al., 2006) and later, FcaPV2 has been frequently and 
specifically amplified from cutaneous SCCs (Munday et al., 2008). While this shows that 
FcaPV2 was the virus most frequently associated with SCCs, the nature of the association is 
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still unclear, since cats are often subclinically infected with FcaPV2 (Munday and Witham, 
2010). A possible hypothesis may be that other co-factors are needed for the development of 
feline skin cancer, as already known for human counterpart and in other species, among these, 
immunosuppression and UV light. Surprisingly, a study that compared SCCs from UV-
protected skin (thus less likely to be caused by UV exposure) to SCCs from UV-exposed skin 
revealed that PV DNA was present significantly more frequently in the UV-protected SCCs. 
Despite the appearent paradox, the detection of significantly different frequencies of PV DNA 
within the two groups of SCCs suggests the virus was not inert and could have contributed to 
the development of neoplasia (Munday et al., 2011). Indeed, as for the human counterpart, the 
“hit and run” hypothesis is considered to be the most likely: in other words, the virus is 
necessary in the first stage of cell tranformation, acting sinergistically with the UV light, but 
the expression of viral genes is not required to sustain malignant progression and virus is no 
longer detectable at later stages of the lesions. In the end, a possible cooperation of PV 
infection with UV light in the development of feline SCCs has to be taken into account 
(Munday et al., 2009, Munday et al., 2011; O’Neill et al., 2011). However, although the high 
frequency of FcaPV2 DNA detection in feline SCCs specimens suggests a possible causal 
association, further evidence that the PV causes neoplasia is required, since alle the studies 
available so far are based only on the association of the viral DNA with skin lesions. 
Additionally, since many cats are infected by FcaPV2, but comparatively few develop SCCs, 
it appears likely that additional cofactors are required for development of neoplasia (Munday 
et al., 2013).  
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Figure 13 
Feline cutaneous SCCs. (A) Cutaneous SCC on the nasal planum of an 21-year-old cat. (B) SCC on the right 
lateral auricular region in a 15-year-old cat (Photos by Dr J. Euclid, University of Sidney, available at 
vetbook.org/wiki/cat/.../Squamous_cell_carcinoma). (C) Photomicrograph of a SCC from the pinna of a cat 
showing the presence of viral cytopathology (koilocytes, black arrows) and corneal pearls (arrowheads) 
(available at http://www.vet.uga.edu/ivcvm/courses/VPAT5200/04_growth/05_carcinogenesis/carcino02.htm 
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Feline sarcoids 
Feline sarcoids are rare neoplasms of domestic cats resembling the equine sarcoids, 
the most common skin neoplasm of horses (Nasir and Campo, 2008). They typically develop 
on the nose, upper lips and digits of young to middle-aged cats from rural areas (Schulman et 
al., 2001). Sarcoids appear as a single, firm and exophytic mass, they may become ulcerated 
and are rarely multiple (Figure 14). Microscopically they show the typical features of equine 
sarcoids, appearing as an expansion of the dermis made by hyperproliferative spindle-shaped 
mesenchymal cells, covered by hyperplastic epidermis (Gross et al., 2005). Feline sarcoids 
have not been reported to metastasise and surgical excision should be curative, despite local 
recurrence can be observed (Schulman et al., 2001). There are no evidences that sarcoids 
permit viral replication. However, PV DNA has been amplified in most of feline sarcoids 
using molecular methods (Schulman et al., 2001; Teifke et al., 2003). Since the PV DNA 
sequence that has been consistently amplified from feline sarcoids (FeSarPV) has never been 
detected in any non-sarcoid feline samples, cats do not appear to be the natural host of this PV 
(Munday et al., 2010). Consistently, FeSarPV is similar to sequences of ruminant PVs and has 
been found in bovine papillomas, as well as in normal bovine skin (Munday and Knight, 
2010). These results suggest that FeSarPV is likely to be a bovine PV and that, similarly to 
equine sarcoids which are caused by cross-species infection with BPV1 or BPV2, feline 
sarcoids are the result of cross-species infection. Interestingly, neither BPV1 nor BPV2 has 
been detected in feline sarcoids and FeSarPV has never been detected in equine sarcoids. 
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Figure 14 
Feline sarcoid.  Exophytic mass present on the nasal philtrum of this cat diagnosed as feline sarcoid 
(https://www.vetstream.com/felis/Content/Disease/dis06228.asp). 
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1.6.2 Oral lesions associated with papillomaviruses in 
domestic cats 
 
Oral papillomas 
Very few cases of feline oral papillomas have been reported in literature. They are 
characterized by well-demarcated sessile or papillomatous proliferations of hyperplastic 
keratinocytes and have been shown to be positive for PVs immunostaining (Sundberg et al., 
2000). Recently, feline oral papillomas showing the typical cytopathology of PVs induced 
lesions have been found to be specifically associated with FcaPV1 (Munday and French, 
2015). Additionally, the recently identified FcaPV4 has been isolated from the salivary duct 
and gingival epithelium showing viral cytopathology (Dunowska et al., 2014).  
 
Oral squamous cell carcinomas  
Oral SCCs are the fourth most common feline neoplasm and are often rapidly 
metastasizing and thus fatal (Munday, 2013). The most affected sites are tongue, mandible 
and the maxilla (Withrow, 2001). In human beings, PVs cause up to 25% of oral SCCs 
(Gillison et al., 2000). On the contrary, PVs DNA has been very rarely detected in feline oral 
SCCs and did never correspond to any FcaPV known so far (Munday et al., 2009; Anis et al., 
2010; O’Neill et al., 2011; Munday et al., 2011c). Currently there is little evidence that PVs 
cause feline oral SCCs, thus further studied are needed to clarify this issue. 
 
 
 
55 
 
1.6.3 Papillomaviral diseases in exotic felids 
PV-induced disease is of potential importance in some highly endangered exotic felids 
and, since some exotic felids are becoming increasingly inbred, they may become more 
susceptible to PV-infections and subsequent epithelial lesions (Rector et al., 2007). 
 
Cutaneous lesions of exotic cats 
PV-induced cutaneous plaques and SCCs have only been reported in snow leopards 
(Uncia uncia); the specific PV has been designated as UuPV1 (Rector et al., 2007). Previous 
works reported PVs infection in viral plaques, mainly on the face and forelimbs, possibly 
evolving to SCCs. The PV type associated to the viral plaques was not determined, but 
appears to be different to UuPV1 (Sundberg et al., 2000; Joslin et al., 2000).  
Sarcoids have been reported in captive African lions (Panthera leo), most frequently 
around the mouth and front limbs; FeSarPV DNA was amplified from these lesions and, since 
the lions were primarily fed un-skinned cattle carcasses, infection from cattle was suspected 
(Orbell et al., 2011). One case of sarcoid has been described also in captive mountain lion 
(Felis concolor), containing PV DNA with 96% similarity to FeSarPV. Despite rare 
recurrance, surgical excision seems to be curative for exotic feline sarcoid (Schulman et al., 
2003). 
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Oral lesions of exotic cats 
PV-induced oral papillomas have been reported in six species of exotic cats. PVs were 
sequenced from lesions of the tongue in Asian lions (Panthera leo persica: PlpPV1) (Sundberg 
et al., 1996); papillomas were more common in lions infected by a lion-specific strain of 
feline immunodeficiency virus, but whether oral papillomas in lions result in significant 
disease is uncertain (Roelke et al., 2009).  
Oral papillomas are associated with UuPV1 in snow leopards and appear as multiple 
small pale nodules on the ventral surface of the tongue (Sundberg et al., 2000; Rector et al., 
2007; Mitsouras et al., 2011). Snow leopards frequently develop oral SCCs and it is possible 
that UuPV1 could cause both papillomas and SCCs in this species. However, UuPV1 DNA 
can be amplified also from oral swabs of animals with no detectable disease (Mitsouras et al., 
2011), so the relationship between this PV and oral neoplasia is still to be proven. 
 A PV aetiology was confirmed by IHC in papillomas from a clouded leopard 
(Neofelis nebulosa) and an Asian desert cat (Felis bieti; Sundberg et al., 1996; Sundberg et 
al., 2000). PVs from oral lesions of bobcats (Lynx rufus) and Florida panthers (Puma 
concolor; Rector et al., 2007) were also sequenced.  
All the PVs sequenced from oral papillomas of exotic felids belong to lambda genus 
and are genetically similar to each other and FcaPV1, suggesting co-speciation of each PV 
and its host (Rector et al., 2007).  
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2. AIM OF THE STUDY 
A consistent number of studies simply suggest an association of FcaPV2 DNA with 
feline skin SCC and precursors; however, expression of FcaPV2 genes in feline skin tumours 
has never been proven. Nevertheless, a consistent detection of the virus in clinically healthy 
skin samples has been reported in domestic cat (Munday, 2013). In general, the presence of 
PVs DNA in samples does not necessary indicate that an active infection is ongoing and that 
it has a role in the skin carcinogenesis.  
Additionally, differently from other PVs proven to be oncogenic, functional in vitro 
models of PVs induced feline skin cancer are completely lacking. Thus, the causative role of 
FcaPV2 in the development of feline SCC and precursors is far from being demonstrated. 
The first aim of this work was to study the expression of viral genes E2, E6 and E7 in a 
subset of cutaneous skin tumours and normal skin samples. 
The second part of this study was focused on the establishment of a new in vitro model 
to investigate the possible transforming activity of FcaPV2, in order to understand possible 
oncogenic properties of viral genes E6 and E7. The molecular pathway of tumour suppressors 
p53 and pRb were investigated, as well as the ability of FcaPV to impair UVB induced 
apoptosis, a well known mechanism triggering PVs induced skin cancer. 
The final results of this study will allow to establish whether FcaPV2 is a causative 
agent or an innocent bystander in feline skin cancer, making a contribution to a poorly 
investigated field in veterinary oncology, and if this may be considered as a general model of 
spontaneous PV-induced cancer, useful for sfurther studies in the field of comparative 
pathology. 
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3. MATERIALS AND METHODS 
 
Samples collection 
 Ten (10) normal skin samples (N1-N10) were collected during routine sterilization 
surgeries at The Veterinary Hospital of Naples Frullone. One oral SCC (T1), eight (8) SCCs 
(T2-T9) and 2 non SCCs skin diseases were also collected (T10 and T11); most of these 
biopsies were taken from hospitalized cats during normal clinical activities at the Department 
of Veterinary medicine and animal Productions of University of Naples Federico II or with 
the help of practitioners from private clinics of differents regions of Southern Italy; other 
samples were sent from University of Veterinary Medicine of Vienna, Austria and from 
University of Agriculture Sciences and Veterinary Medicine, Ion Ionescu de la Brad, Iasi, 
Romania. All the samples were from cats of european short-hair breed, except for T9 that was 
collected from a Siamese cat. The anatomical site of the lesions was not known for most of 
the samples; T1 was an oral SCC of the mandible, T7 SCC was removed from the right ear, 
T9 from the left side of the face, T11 from the right forepaw. All the biopsies were collected 
under local or total anaesthesia without causing pain or any kind of suffering to the animals; 
sample T1 was removed from an euthanized cat suffering from a devasting oral SCC. After 
surgical excision, the samples were immediatey submerged in RNAlater® RNA stabilization 
solution (Life Technologies) in 1,5 mL tubes and stored at -80 °C in order to preserve the 
integrity of both DNA and RNA. 
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DNA and RNA extraction 
 Samples were removed from RNAlater® and approximatively 20 mg of tissue were 
cut with sterile disposable scalpels. Total DNA was extracted using DNeasy Blood & Tissue 
Kit (Qiagen #69504) according to the manufacturer’s protocol. 
 Cellular RNA was obtained using RNeasy Mini Kit (Qiagen #74104) following the 
brand recommendations. Sample T8 and T9 were not available for RNA extraction. 
 The DNA and RNA concentrations of each sample were measured using a 
spectrophotometer. 
 
Polymerase chain reaction (PCR) and Reverse Transcription (RT)-PCR 
DNA samples were subjected to PCR amplifying a specific fragment of FcaPV2 L1 
gene. FcaPV2 genome cloned into pBluescript II-KS+ vector was kindly provided by Prof. 
C.E. Lange (Dermatology Unit, Clinic for Small Animal Internal Medicine, Vetsuisse 
Faculty, Zurich, Switzerland) and was used as positive control of the reaction. The primers 
sequences, the size of amplified fragment, and the annealing temperatures are summarized in 
Table 1. PCR conditions were as follows: initial denaturation at 95 °C for 5’, followed by 36 
cycles at 95 °C for 30” (denaturation), Tm °C for 30” (annealing), and 72 °C for 30” 
(extension), with a final extension at 72 °C for 5’. PCR products were separated by 
electrophoresis in 1,5 % agarose gels with Tris borate ethylene diamine tetra acetic acid 
(EDTA) buffer (TBE; 89 mM Tris base, 89 mM Boric acid, and 2 mM EDTA), stained with 
ethidium bromide, and visualised under ultraviolet light. Amplicons were purified using the 
MiniElute Gel Extraction Kit (Qiagen #28606) following manufacturer’s instructions and sent 
to “Research Center CEINGE Advanced Biotechnologies” for sequencing. The sequences 
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were aligned to FcaPV2 L1 gene sequence using Basic Local Alignment Search Tool 
(NCBI/BLAST). 
 Reverse transcription (RT) to cDNA was performed on 500 ng of each RNA sample 
using iScript™ cDNA Synthesis Kit (Bio-Rad #170-8891) according to manufacturer’s protocol. 
PCR was carried out to amplify specific fragments of E2, E6 and E7 FcaPV2 genes and feline 
GAPDH in 25 µl of reaction mixture, containing 50 ng of cDNA from each sample, 2 mM 
MgCl2, 200 µM each dNTP, 480 nM of each primer and 2.5 U of AmpliTaq Gold DNA 
Polymerase (Applied Biosystems). The PCR protocol was the following: initial denaturation 
step of 5‘ at 95 °C, then 36 cycles of amplification with a denaturation step at 95 °C for 30”, 
an annealing step at specific Tm °C for 30” and an extension step at 72 °C for 30”. A final 
extension step at 72 °C for 5’ was performed in each PCR assay. For detection of E7, a 
second PCR using 1 uL of the first PCR product as stamp was necessary for samples T1, T3, 
T4 and T5. The same reactions were performed in parallel on FcaPV2 genome cloned in 
pBluescript II-KS+ as positive control of the amplifications (not shown). The primers sets, the 
size of amplified fragments and the annealing temperatures are summarized in Table 1. 
Detection of the amplified products was carried out by electrophoresis on 1,5 % ethidium 
bromide-stained agarose gel. Amplicons were purified using the MiniElute Gel Extraction Kit 
(Qiagen #28606) following manufacturer’s instructions and sent to “Research Center 
CEINGE Advanced Biotechnologies” for sequencing. Alignment of the sequences with 
FcaPV2 E2, E6 and E7 genes was performed using NCBI/BLAST. 
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Cells and cells culture 
Crandel-Rees feline kidney (CRFK) cells were purchased from ATCC® cell bank. 
NIH3T3 mouse fibroblasts cell line and HaCat immortalized human keratinocytes was 
available in the laboratory of Infections and Cancer Biology Group (ICB) at International 
Agency for Research on Cancer (IARC), Lyon, France, where most of this work was 
developed. Phoenix cell line, developed from the 293T cell line transformed with adenovirus 
E1a and carrying a temperature sensitive T antigen (Nolan laboratory, Stanford University) 
was already available at IARC as well. This cell line can be used as a packaging line since it 
carries a construct capable of producing gag, pol and env proteins for ecotropic and 
amphotropic viruses to act in trans. 
CRFK, NIH3T3, Phoenix and HaCat cells were cultured in Dulbecco's modified 
Eagle's medium (DMEM) with high glucose, supplemented with 10% fetal bovine serum 
(FBS) (PAA), 100 U/mL penicillin and 100 μg/mL streptomycin (Pen Strep, Gibco, Invitrogen), 
2 mM L-glutamine (PAA) and 10 μg/mL ciprofloxacin hydrochloride (EUROMEDEX). 
Human primary keratinocytes (HPK) from 2 different donors were obtained by the 
“Laboratoire des Substituts Cutanes”, Hopital E. Herriot (Lyon, France). Primary cells were 
cultured in FAD medium, composed with: 25% DMEM (PAA), 75% Ham’s F12 (PAA), 5% 
FBS (PAA), 100 U/mL penicillin and 100 μg/mL streptomycin (Pen Strep, Gibco, 
Invitrogen), 10 μg/mL Cyprofloxacine (EUROMEDEX), 10 ng/mL epidermal growth factor 
(EGF, R&D), 10 mM Cholera toxin (List Biological Laboratories INC.), 400 ng/mL 
hydrocortisone (Sigma), 24 ug/mL Adenine (Sigma), 5 μg/mL human Insulin (Sigma). 
  All cell lines were grown at 37 °C in humified atmosphere at 5% CO2. In order to form 
colonies, the keratinocytes must be suitably supported by fibroblastic cells, in particularly by 
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soluble products elaborated by the fibroblasts (Green et al., 1977). Thus, HPK were co-
cultured with a feeder layer of NIH3T3 previously treated with Mytomicin (Sigma) for 2 h to 
arrest cell division in order to avoid overgrowing in co-culture flasks. The feeder layer was 
changed every 2 days and at each passage of HPK. 
 
Cloning strategies and Constructs 
The whole operon E6E7 and the E6 and E7 genes individually, were cloned into 
pCEFL-HA using standard procedures for molecular cloning. Firstly, the different genes were 
subcloncloned by PCR from FcaPV2 genome cloned into pBluescript II-KS++, using specific 
primers containing sites for EcoRI and XbaI restriction enzymes (RE). The PCR reactions 
were carried out using the reagents and protocols assessed above; primers details are 
summarized in Table 1. The PCR products corresponding to E6E7, E6 and E7 genes and th 
pCEFL-HA vector were double-digested with EcoRI and XbaI RE (New England Biolabs, 
NEB) following manufacturer’s instructions, at 37 °C for 2h. After purification of the 
digestion products using the QIAquick® PCR Purification Kit (Qiagen #28106), digested 
pCEFL-HA was dephosphorylated using Rapid DNA Dephos&Ligation kit (Roche 
#04898117001) to avoid self-ligation. Following another step of purification of the digested 
and dephosphorylated pCEFL-HA with the same aforementioned kit, the final products wer 
subjected to ligation reaction using DNA Ligation Kit (TAKARA BIO INC. #6021), 
according to manufacturer’s recommendations. Ligation products were transformed by heat 
shock (30’ on ice, 45” at 42 °C, 2’ on ice) in Subcloning Efficiency™DH5α™Competent 
Cells (Invitrogen) and the final constructs consisting in pCEFLE6E7, pCEFLE6 and 
pCEFLE7 were purified by maxiprep using Plasmid Maxi Kit (Qiagen #12263). 
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The pLXSN vector was available at ICB laboratory at IARC. The whole operon E6E7, 
E6 and E7 ORFs were subcloncloned by PCR using specific primers containing sites for 
EcoRI and BamHI RE. The PCR reactions were carried out using the reagents and protocols 
assessed above; primers details are summarized in Table 1. The PCR products corresponding 
to E6E7, E6 and E7 genes and the empty pLXSN vector were double-digested with EcoRI 
and BamHI RE (Thermo Scientific) following manufacturer’s instructions, at 37 °C for 2h. 
The digestion products were run in agarose gel and then purified by using the MiniElute Gel 
Extraction Kit (Qiagen #28606). The digested pLXSN was dephosphorylated using Shrimp 
Alkaline Phosphatase (SAP) kit (USB Corporation #70092Z) to avoid self-ligation. Following 
another step of purification by gel extraction of the digested and dephosphorylated pLXSN 
using the same aforementioned kit, the final products wer subjected to ligation reaction using 
the Ligase T4 ligation kit (Roche #10481220001) according to manufacturer’s 
recommendations. Ligation products were transformed by heat shock (30’ on ice, 45” at 42 
°C, 2’ on ice) in Subcloning Efficiency™DH5α™Competent Cells (Invitrogen) and the final 
constructs consisting in pLXSNE6E7, pLXSNE6 and pLXSNE7 were purified by midiprep 
using PureLink® HiPure Plasmid Midiprep Kit (Invitrogen). 
To generate recombinant bacterial fusion proteins, FcaPV2 E6 and E7 genes were 
cloned in the glutathione-S-transferase (GST) fusion vector pGEX4T1. HPV16 E6 and E7 
cloned respectively in pGEX4T1 and pGEX2T1 vectors were already available at ICB 
laboratories. FcaPV2 E6 and E7 were subcloned by PCR using specific primers containing 
sites for EcoRI and NotI RE. The PCR reactions performed using the reagents and protocols 
assessed above; primers details are summarized in Table 1. The PCR products corresponding 
to E6 and E7 genes and the empty pGEX4T1 vector were double-digested with EcoRI and 
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NotI RE (Thermo Scientific) following manufacturer’s instructions, at 37 °C for 2h. The 
digestion products were run on agarose gel and then purified by using the MiniElute Gel 
Extraction Kit (Qiagen #28606). The digested pGEX4T1 was dephosphorylated using Shrimp 
Alkaline Phosphatase (SAP) kit (USB Corporation #70092Z) to avoid self-ligation. Following 
another step of purification by gel extraction of the digested and dephosphorylated pGEX4T1 
using the same aforementioned kit, the final products wer subjected to ligation reaction using 
the Ligase T4 ligation kit (Roche #10481220001) according to manufacturer’s 
recommendations. Ligation products were transformed by heat shock (30’ on ice, 45” at 42 
°C, 2’ on ice) in One Shot® MAX Efficiency® DH5α™-T1R Competent Cells (Invitrogen) 
and the final constructs consisting in pGEX4T1FcaPV2 E6 and pGEX4T1FcaPV2 E7 were 
purified by maxiprep using PureLink® HiPure Plasmid Maxiprep Kit (Invitrogen). 
 
Transfection and retroviral transduction procedures  
CRFK cells were plated at 4x106 in 100mm petri dishes. After 24 h, cells were 
transfected with empty pCEFL-HA vector, pCEFLE6E7, pCEFLE6 and pCEFLE7 using 
Lipofectamine®2000 (Life Technologies) following the instructions provided by the 
manufacturer. Cells were splitted 48 h after transfections and subjected to selection by adding 
neomicin 500 μg/mL to the growth medium. Cells selected by resistance to the antibiotic 
conferred by the vector were pooled after 2 weeks and tested for the expression of the 
transfected genes by RT-PCR as described above using the same primers designed for 
cloning.   
Phoenix cells were plated in 100mm petri dishes. After 24 h, when cells reached a 
50/70% confluence, they were transfected with empty pLXSN, pLXSNE6E7, pLXSNE6 and 
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pLXSNE7 using CalPhos Mammalian transfection kit (K2051-1 BD-Biosciences). Briefly, 
samples were prepared as follows: 10 µg of the DNA corresponding to each construct were 
mixed with 440 µl of H2O and 62 µl of CaCl2 (stock 2M) in a 15 ml tube and then 500 µl of 
HBS (2X) were added drop by drop to obtain 1 mL of transfection solution. Growth medium 
was replaced by 5mL of fresh one added with Cloraquine at 25µM final concentration and the 
transfection solution was added drop by drop. After 6 h the medium was changed with fresh 
complete DMEM and 24 h after transfection it was changed again. Further 24 h later the 
medium of transfected cells containing the retroviral particles was collected and passed twice 
through 0.22 µm filters. The retroviral suspension was added with 5uL of Polybren (from a 
stock 5mg/mL) and applied to HPK monolayer. After 6 h it was removed and replaced by 
complete fresh FAD medium. Cells were splitted 1:1 24 h after the infection and neomycin 
(0,1mg/mL final concentration) was added to the culture medium to start selection of 
transduced cells to be ended after 5 days. 
 
UVB irradiation  
For UVB irradiation, 3,5 x 106 CRFK cells were plated in 6 well plates. After 24 h, 
when cells were at 60-70% confluence, growth medium was removed and 400 uL of PBS 
were added to each well to avoid the cell monolayer to get dry during irradiation. Thus cells 
were irradiated at 25 mJ/cm2 (0,025 J/cm2) using BIO-SUN irradiation system 365/312nm 
(Vilbert Lourmat, France) and PBS was replaced by fresh medium. For not irradiated cells 
used as control, medium was simply replaced by fresh one after a washing in 400 uL of PBS. 
All the cells were harvested after 8 h to be analyzed by Western blotting or qPCR.  
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Western blotting procedures and antibodies  
To prepare whole cell protein extracts for Western blotting analysis, cells were lysed 
using RIPA buffer (50mM Tris, 150mM NaCl, 1% Triton X-100, 1mM EDTA, 0,25 % 
Deoxicholate) added with protease and tyrosin and serine-threonine phosphatase inhibitors 
cocktails (10 uL for each mL, Sigma), for 20’ on ice. Cell lysates were clarified by 
centrifugation at 13000 rpm for 10’ at 4 °C. Protein concentration was measured by BCA 
protein assay performed according to manufacturer protocol. Equal amounts of each protein 
sample were mixed to Laemmli sample buffer (sodiumdodecyl sulphate (SDS), Tris-HCl pH 
6,8%, glycerol, bromophenol blue, and β-mercaptoethanol), boiled and loaded onto 
polyacrylammide gels to be subjected to separation by electrophoresis. Proteins were 
transferred onto PVDF membranes using IBlot II apparatus (Life Technologies). Membranes 
were incubated with 5% Non Fat Dry Milk (NFDM) in Phosphate Buffered Saline (PBS) 
0,1% Tween-20 (PBST) for 1 h at room temperature (rt), to block aspecific bindings, and then 
the primary antibodies diluted in PBST 5% NFDM were applied over night (O/N) at 4 °C 
with gentle agitation. After washing steps in PBST, membranes were incubated with 
appropriate secondary antibodies conjugated with Horseradish Peroxidase (HRP) (mouse or 
rabbit HRP linked immunoglobulins, depending on the species of the primary antibody, 
Promega) for 1h at rt. Following further washings in PBST, bound antibodies were visualized 
by enhanced chemiluminescence (ECL, Clarity™ ECL Western Blotting Substrate, Bio-Rad). 
Protein levels were quantitatively estimated by densitometric analysis using ChemiDoc gel 
scanner (Bio-Rad) equipped with a densitometric workstation (Image Lab software, Bio-Rad).  
 For the analysis of p53 pathway, rabbit anti-human p53 (Santa Cruz, sc-6243) and 
rabbit anti-human p21 (Santa Cruz, sc-397) were used at 1:1000 dilution. 
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 For the biochemical detection of apoptosis, rabbit anti-human Caspase3 (Cell 
Signaling #9662), rabbit anti-human Bax (Santa Cruz, sc-493) and Bak (Santa Cruz, sc-7873) 
antibodies were applied, at 1:1000 dilution for the two formers, 1:500 for the latter. 
 The proteins of the pRb pathway were detected using mouse anti-human pRb (BD 
Pharmingen #554136), rabbit anti-human Cycline A (Santa Cruz, sc-751) and mouse anti- 
human Cdc2 (Santa Cruz, sc-54) at 1:1000 dilution. 
  All the blots were stripped and reprobed with mouse anti-human β-actin antibody 
(Calbiochem) to allow normalization. 
  
RNA extraction and Real-time quantitative PCR (Real-time qPCR) 
 Total RNA was extracted from cells using the Absolutely RNA Miniprep Kit (Agilent, 
#400800) following the manufacturer recommendations. Sample concentrations were 
calculated by a spectrophotomer and RT was performed on 500 ng of total RNA using 
RevertAid H Minus First Strand cDNA Synthesis Kit (Thermo Scientific #K1632); 50 ng  of 
cDNA were used to prepare serial dilutions, which were subjected to qPCR for feline p53, 
Bcl-Xl, Cdc2, cMyc using Mesa Green qPCR Mastermix Plus (RT-SY2X-06+WOULR, 
Eurogentec) according to the brand instructions and run in Mx3005P qPCR System (Agilent 
Technologies) with the following protocol: 95 °C 10’,  followed by 95 °C 15’’, Tm °C 45 “, 
72 °C 45” (45 cycles),  95 °C 1’, 55 °C 30”, 95 °C 30”. Amplification of feline GAPDH was 
performed in parallel to allow normalization of the results.The primers sequences and the 
specific Tm °C are summarized in Table 1. The results were analyzed using the software 
provided by the machinery.  
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GST pull-down assay 
 Recombinant bacterial fusion proteins were generated cloning the appropriate PVs E6 
and E7 genes in the glutathione-S-transferase (GST) fusion vector pGEX4T1 and pGEX2T1 
as described above. 
The empty vector pGEX4T1, FcaPV2 E6, FcaPV2 E7 and HPV16 E6 cloned in 
pGEX4T1 and HPV16 E7 cloned in pGEX2T1 were transformed (~3 ug) by thermal shock 
(30' on ice, 45'' at 42°, 2' on ice) in Rosetta™ competent bacterial strain (Life Technologies). 
Cells were resuspended in 250 uL of Sock medium and incubated at 37° in agitation for 45'. 
Fifty uL of each cell suspension were plated on LB-Agar plates added with Ampicillin 
100ug/mL (LB Amp+) and let grow O/N. 
Grown colonies for each construct were picked and grown O/N in snapcap tubes in 5 mL of 
LB Amp+. Of each cell suspension, 1 mL was added to 100 mL of LB Amp+ and grown 
overday monitoring the OD600nm. When bacterial suspensions reached an OD600nm of 0,4, 
Isopropyl β-D-1-thiogalactopyranoside (IPTG) was added to the bacterial suspension at 0,1 
mM final concentration to stimulate fusion proteins sinthesys. Each culture was grown for 
further 4 hours at 30 °C and the bacteria were collected by centrifugation. For cell lysis and 
protein purification, the bacterial pellets were resuspended in 2 mL of NETN buffer (20mM 
Tris-HCl pH8, 10mM NaCl, 0,5 % Nonidet p40, 1mM EDTA, 1mM NaF) added with 
protease and phosphatases inhibitors and subjected to sonication on ice in a Branson Sonifier 
250 (4 cycles of 20” with an interval of 1’ on ice between cycles). The insoluble bacterial 
debris was removed by centrifugation at 10000 rpm for 15’ and the supernatant was filtered 
through steyle 0,45 μm filter to obtain a clear bacterial extract. 
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The fusion proteins were purified by incubating the bacterial lysates with 75 uL of 
Glutathione Sepharose-4B (GelHealthcare) previously washed in 0,5% NFDM NETN buffer, 
at 4 °C for 1h on rotating wheel. The beads were finally recovered by centrifugation (1’ at 
6000 rpm at 4 °C) and washed 5 times with NETN buffer to grant purity of the preparation.   
 Expression and purity of the recombinant proteins was verified by SDS 
polyacrylammide gel electrophoresis followed by Comassie Blue staining: 10 uL of each 
beads-GST-fused proteins were added with 10 uL of Laemmly sample buffer 5X, boiled and 
cenrifugated, and then the supernatant was loaded onto 12% poliacrylammide gel. The gel 
staining allowed an approximative quantization and to check the purity of the obtained fusion 
proteins. 
  HaCat and CRFK cells were lysed in IP buffer (Tris pH 7.5 20mM, NaCl 200mM, 
EDTA 1mM, NP-40 0,5%) added with protease and phosphatase inhibitors as described 
above; 0,6 mg of whole cell lysates were incubated first with 5 uL of GST-Sepharose beads 
for 30' at 4 °C in rotation to allow a preclearing of non specific bindings to GST, then with 
equal amount of GST and GST fusion proteins-beads complexes for 1h at 4 °C. The beads 
were collected by centrifugation and washed 5 times with NETN buffer. They were 
resuspended in 10 uL of Laemmli sample buffer 5X, boiled, centrifugated and the supernatant 
was loaded onto appropriate SDS polyacrylamide gels. The samples were subjected to 
Western blotting for p53 and pRb detection as described above. 
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HPK immortalization assay 
 To check the immortalization or life-span prolonging ability of FcaPV2 putative 
oncogenes, HPK were transduced with empty pLXSN vector, pLXSNE6E7, pLXSNE6 and 
pLXSNE7. After selection, transduced cells were cultured for several passages. Simply, cells 
obtained after selection were assumed to be at population doubling (PD) 0. When reaching a 
confluence of~80%, cells were splitted 1:2 and they were considered to be at PD 1; at the 
second splitting 1:2, the PD 2 was counted, and so on. Since no immortalization phenomenon 
could be observed, cells were kept in culture until they underwent senescence and cell death 
and the PD number of oncogenes tranduced cell lines were compared to cell selected for 
empty pLXSN and to each other.  
 
Statistical analysis 
 For statistical analysis, independent sample t-test (p<0.05 and/or p<0,01) was 
performed using SPSS 13 software. 
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Application Genes Primers sequences Tm °C Fragments 
size 
PCR 
 
L1 Fw: 5'-GACACTACACGCGGTACCAA-3' 
Rev: 5'-GGTAAGAGTGACCACGCACA-3' 
60 °C 150 bp 
 
 
 
RT-PCR 
E2 Fw: 5'-CTGGTTTGGCCGGACACTAT-3' 
Rev: 5'-ATCCGTCCGGAACTTCACAC-3' 
60 °C 126 bp 
E6 Fw: 5'-TACGAGCGCGAGCATTTTTG-3' 
Rev: 5'-TGCAGCTTTTCTCCTGGTGT-3'  
59,9 °C 134 bp 
E7 Fw: 5'-TTGGCACGACACCTACCATT-3' 
Rev: 5'-ACTGCACACTCCACAGGGTA-3' 
59,6°C 167 bp 
GAPDH Fw: 5'-CCATGTTTGTGATGGGCGTG-3' 
Rev: 5'-TGATGGCATGGACTGTGGTC-3' 
60 °C 159 bp 
 
 
Cloning in 
pCEFL-HA 
RT-PCR 
E6E7 Fw: 5’-AATTGAATTCGAGCGTCCTCGCACGGCT-3’ 
Rev: 5’-AATTTCTAGACCCGTCCAGGTCACTACACT-3’ 
60 °C 784 bp 
E6 Fw: 5’-AATTGAATTCGAGCGTCCTCGCACGGCT-3’ 
Rev: 5’-AATTTCTAGAGGTGCCTCCAGCAGTACAATG-3’ 
61,3 °C 463 bp 
E7 Fw: 5’-AATTGAATTCATTGGCACGACACCTACCAT-3’ 
Rev: 5’-AATTTCTAGACCCGTCCAGGTCACTACACT-3’ 
59 °C 368 bp 
 
 
Cloning in 
pLXSN 
E6E7 Fw: 5’-AAAAGAATTCATGGAGCGTCCTCGCACG-3’ 
Rev: 5’-AAAAGGATCCCTAGATGTAGCGTCTACT-3’ 
60 °C 723 bp 
E6 Fw: 5’-AAAAGAATTCATGGAGCGTCCTCGCACG-3’ 
Rev: 5’-AAAAGGATCCTTATTGCAGGTACCTGCACAG-3’ 
62 °C 437 bp 
E7 Fw: 5’-AAAAGAATTCATGATTGGCACGACACCT-3’ 
Rev: 5’-AAAAGGATCCCTAGATGTAGCGTCTACT-3’ 
50 °C 308 bp 
 
Cloning in 
pGEX4T1 
E6 Fw: 5'-AAAAGAATTCATGGAGCGTCCTCGCACG-3' 
Rev: 5'-AAAAGCGGCCGCTTATTGCAGGTACCTGCACAG-3' 
62 °C 439 bp 
E7 Fw: 5'-AAAAGAATTCATGATTGGCACGACACCT-3' 
Rev: 5'-AAAAGCGGCCGCCTAGATGTAGCGTCTAGT-3' 
50 °C 310 bp 
 
 
 
 
Real-time 
qPCR 
p53 * Fw: 5’-GCGCCTATGGTTTCCATTTA-3’ 
Rev: 5’-GGCAAAACAGCTTGTTGAGG-3’ 
60 °C 237 bp 
Bcl-Xl Fw: 5’-GGAGCTGGTGGTTGACTTTC-3’ 
Rev: 5’-AGGATGGGTTGCCATTGAT-3’ 
60 °C 237 bp 
Cdc2 Fw: 5’- CCCCCAATAATGAAGTGTGG-3’ 
Rev: 5’-CCATTTTGCCAGAAATTCGT-3’ 
60 °C 176 bp 
cMyc Fw: 5’-CAAAAGGTCGGAATCGGGGT-3’ 
Rev: 5’-CGTGGCATCTCTTAAGGACCA-3’ 
60 °C 83 bp 
GAPDH Fw: 5'-CCATGTTTGTGATGGGCGTG-3' 
Rev: 5'-TGATGGCATGGACTGTGGTC-3' 
60 °C 159 bp 
 
Table 1. Details of PCR primers used throughout the work for each application and each gene. The 
nucleotide sequences, the annealing temperatures (Tm °C) and the size of amplified fragments are 
indicated (bp:base pairs) (* from Mochizuchi et al., 2012 ) 
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4. RESULTS 
4.1 FcaPV2 E2, E6 and E7 genes are expressed in feline 
SCC in vivo  
To assess whether FcaPV2 was biologically active in feline skin cancer and to 
hypothesize a role in the pathogenesis of these tumours, we aimed to demonstrate putative 
viral oncogenes expression in a series of feline SCCs, non SCC skin lesions and normal skin 
biopsies. 
Firstly, 10 normal skin samples (N1-N10), 1 oral SCC sample (T1), 8 cutaneous SCCs 
(T2-T9), 1 epithelial dysplasia of unknown origin (T10) and 1 sarcoma sample (T11) were 
analyzed by PCR amplifying a specific fragment of FcaPV2 L1 gene to check for the presence 
of viral DNA. A band of the expected molecular size was amplified from 4 out of 10 (40%) 
normal skins (N1, N2, N5, N9), from the oral SCC (T1) and from 8 out of 8 (100%) 
cutaneous SCCs (T2-T9); the epithelial dysplasia (T10) and the sarcoma sample (T11) were 
negative for viral DNA (data not shown). The amplicons from samples T1 and N5 were 
sequenced, revealing a 92% and 95% of sequence homology with the specific fragment of 
FcaPV2 L1.  
 RNA could be extracted from 4/4 DNA positive normal skins, from the oral SCC and 
from 7/8 DNA positive cutaneous SCCs and analyzed by RT-PCR to check for E2, E6 and E7 
genes expression. The fragments of E2 and E6 genes were successfully amplified from 
samples T1, T3, T5, T6 and T7 (Figure 15A).  The E7 amplicons were detected in samples 
T6 and T7, while a second amplification reaction on the first PCR products was necessary to 
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detect E7 amplicons in samples T1, T3, T4 and T5 (Figure 15B). Among the 4 normal skins 
analyzed, N1 was potitive for E2, E6 and E7 expression, whilst only E6 could be amplified 
from N2. GAPDH was amplified to chek the quality of the RNA and it was detected in all the 
samples (Figure 15A). E2, E6 and E7 amplicons from T6 and T7 were sequenced revealing 
96% sequence homology with the FcaPV2 E2 for both, 94% and 97% with E6, and 100% and 
94% with E7, respectively. E2 fragment amplified from N1 was 99% identical to the E2 
sequence, whilst the E6 fragment sequenced from N2 showed 93% homology with the 
corresponding FcaPV2 gene.  
In summary, 100% of SCCs (including 1 oral and 7 cutaneous samples), none of the 
non SCC skin diseases and 40% of normal skins were positive for viral DNA. Most 
importantly, the virus was found to be transcriptionally active in the 89% of the analyzed 
DNA positive feline SCC samples versus the 50% of DNA positive normal skins. E2 protein 
is involved in viral transcription and viral genome replication, whilst E6 and E7 are 
considered as putative oncogenes for analogy with other oncogenic PVs known so far. Thus, 
taken toghether, these findings demonstrate that FcaPV2 in biologically active in vivo and 
plays a causative role in the development of feline oral and skin cancer.  
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Figure 15 
FcaPV2 is transcriptionally active in feline SCC in vivo. (A) E2 and E6 mRNA were detected in 5/7 tumor 
samples and in 1/2 normal skins; E7 was readily found to be expressed in 2 SCC and in 1 normal skin. GAPDH 
was successfully amplified from all the samples ensuring adequate RNA quality. (B) When performing a second 
amplification on the first PCR products, E7 expression was detected also in 4/5 of the additional samples 
analyzed. Representative panels from RT-PCR are shown. 
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4.2 Expression of FcaPV2 E6 and E7 oncogenes in feline 
epithelial cells CRFK 
 To establish an in vitro model of FcaPV2 associated feline skin cancer, feline 
epithelial cells CRFK were transfected with pCEFLE6E7 (CRFKE6E7). To further 
understand which among E6 and E7 genes was responsible for the biological effects to be 
investigated, pCEFLE6 and pCEFLE7 were also transfected individually (CRFKE6, 
CRFKE7). Once subjected to selection by the antibiotic resistance conferred by the vector, 
transfected cells pools were obtained and analyzed by RT-PCR for the expression of the 
transfected genes. As expected both E6 and E7 were succesfully amplified from CRFKE6E7, 
while only E6 and only E7 were expressed in CRFKE6 and CRFKE7, respectively; the 
specificity of PCR bands was ensured by using FcaPV2 genome as positive control and 
GAPDH cDNA, amplified to check the quality of the starting RNA, was detected in all the 
cell lines. (Figure 16). The amplicons corresponding to E6 and E7 genes were sequenced, 
revealing a 100% homology with FcaPV2 E6 and E7 sequences. 
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Figure 16 
Expression of FcaPV2 oncogenes in feline epithelial cell lines CRFK. A representative RT-PCR gel showing 
mRNA expression of the indicated FcaPV2 putative oncogenes in transfected CRFK cells. 
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4.3 FcaPV2 impairs p53 at protein level upon E6 
expression, while E7 downregulates p53 mRNA 
 Since tumour suppressor p53 is the cellular target most frequently impaired in PVs 
induced cancers, we firstly aimed at assessing the p53 protein levels in CRFKE6E7, CRFKE6 
CRFKE7 by Western blotting analysis on whole cell lysates: Figure 17A shows that p53 
protein is significantly downregulated in CRFKE6E7, CRFKE6 and CRFKE7 when 
compared to control cells (CRFKpCEFL), as confirmed by densitometric analysis normalized 
for β-actin on three independent experiments (Figure 17B).  
While E6 from HR mucosal HPVs and from several cutaneous HPVs is known to 
degrade p53 protein, no mechanisms by E7 are known to impair p53 protein. To further 
investigate the mechanisms of p53 downregulation by E7, Real-time qPCR was performed on 
cDNA retrotranscribed from total RNA extracted from all the cell lines, twice in technical 
duplicate. As shown in Figure 17C, p53 was found to be downregulated at mRNA level 
specifically upon E7 expression, suggesting different and unreported mechanisms by this 
oncogene aimed at affecting p53 expression. 
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Figure 17 
FcaPV2 oncogenes impair p53 levels. (A) A representative Western blotting showing dowregulation of p53 in 
cells expressing E6E7, E6 and E7. (B) Mean densitometric values normalized to β-actin and SD from 3 
independent experiments. (C) FcaPV2 downregulates p53 mRNA level upon E7 expression; Real-time qPCR 
data from independent experiments normalized for GAPDH are shown. (*p<0,05; **p<0,01). 
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4.4 FcaPV2 oncogenes impair p53/p21 UVB responsive 
pathway 
 Several skin PVs are known to inhibit UVB induced cell cycle arrest through 
impairing p53/p21 pathway, mainly reducing p53 protein levels or its function through post-
translational modifications, constituting therefore a possible mechanisms triggering skin 
carcinogenesis. To assess whether FcaPV2 is able to counteract p53/p21 responsiveness to 
UVB in our feline model, cells were irradiated with UVB light at 25 mJ/cm2 and subjected to 
Western blotting for p53 and p21 after 8 h (Figure 18A). Importantly, the results confirmed 
the lower p53 protein levels in all the cell lines expressing the oncogens compared to control 
cells. As expected, p53 accumulation could be observed in CRFKpCEFL after UVB 
treatment, whilst almost undetectable protein augmentation was detected in CRFKE6E7, 
CRFKE6 and CRFKE7. Data from 3 independent experiments were normalized for β-actin 
levels and are presented as fold increase compared to the internal not irradiated control for 
each cell line put as 1 (Figure 18B). Consistently, p21 was accumulated in CRFKpCEFL 
treated with UVB, but not in other cell lines. Densitometric analysis normalized for β-actin 
from 3 independent experiments yielding comparable results is shown (Figure 18C). These 
results indicate that p53 downregulation by FcaPV2 oncogenes leads to its non-
responsiveness to UVB irradiation. As a consequence, cells do not undergo p21-induced cell 
cycle arrest, suggesting that this common mechanism at the basis of PVs induced skin cancer 
is shared also by FcaPV2. 
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Figure 18 
FcaPV2 oncogenes impair p53/p21 UVB responsive pathway. (A) p53 and p21 are upregulated after UVB 
irradiation (25 mJ/cm2) in control cells CRFKpCEFL but not in cells expressing E6E7, E6 and E7;  
representative Western blotting are shown. (B) Mean densitometric values normalized to β-actin and SD from 3 
independent experiments for p53 are presented as fold increase relative to not irradiated control for each cell 
line. (C) Mean densitometric values normalized to β-actin and SD from 3 independent experiments for p21. 
(*p<0,05). 
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4.5 FcaPV2 counteracts UVB induced apoptosis 
 Several cutaneous HPVs belonging to genus beta are know to impair UVB induced 
apoptosis, in order to counteract cell death and keep an high proliferative epithelium which 
may favour viral replication. Here, we show that FcaPV2 is able to counteract UVB induced 
apoptosis in feline epithelial cells. Western blotting analysis revealed that Caspase3 was 
highly cleaved in CRFKpCEFL after UVB exposure, while almost no cleavage could be 
detected in all the cell lines expressing the different oncogenes (Figure 19A). Consistently, a 
signficant accumulation of pro-apoptotic proteins Bax and Bak could be observed in UVB 
exposed CRFKpCEFL but not in CRFKE6E7, CRFKE6 and CRFKE7 (Figure 19A); 
densitometric data normalized for β-actin from at least two independent experiments are 
shown (Figure 19B, C, D). Bcl-Xl is a pro-survival protein which inhibits Bak pro-apoptotic 
function and is downregulated in apoptotic cells. As expected, Real-time qPCR showed that 
Bcl-Xl gene expression is downregulated in irradiated control cells, while its mRNA levels 
remain stable in cells expressing E6E7 and E6 when treated with UVB. Despite less potently, 
E7 inhibits Bcl-Xl downregulation as well. Figure 19E shows mean values and standard 
deviations (SD) from three independent experiments performed in technical duplicate, 
normalized for GAPDH. These results strongly suggest that FcaPV2 impairs UVB induced 
apoptosis, as already known for cutaneous HPVs. This effect is likely to be, at least in part, 
linked to p53 downregulation and its lower responsiveness to UVB assessed above. 
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Figure 19 
(continued on following page) 
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FcaPV2 oncogenes counteracts UVB induced apoptosis. (A) Caspase3 is cleaved  after UVB irradiation (25 
mJ/cm2) in control cells CRFKpCEFL but not in cells expressing E6E7, E6 and E7; consistently, a signficant 
accumulation of pro-apoptotic proteins Bax and Bak could be observed in UVB exposed CRFKpCEFL but not in 
CRFKE6E7, CRFKE6 and CRFKE7; representative Western blotting are  shown. (B) Mean densitometric values 
normalized to β-actin and SD from independent experiments for Caspase3 are shown. (C), (D) Mean 
densitometric values normalized to β-actin and standard deviations SD from independent experiments for Bak 
and Bax are presented as fold increase relative to not irradiated control for each cell line. (E) Anti-apoptotic Bcl-
Xl gene expression is downregulated in irradiated CRFKpCEFL cells, while its mRNA levels remain stable in 
cells expressing E6E7 and E6 when treated with UVB. Despite less potently, E7 inhibits Bcl-Xl downregulation 
as well. Mean values and SD from independent Real-time qPCR experiments normalized for GAPDH are shown 
(*p<0,05).  
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4.6 pRb pathway is impaired in cells expressing FcaPV2 
oncogenes 
 The E7 from HR HPVs and some beta cutaneous HPVs inhibits pRb function thorugh 
different mechanisms, among these the direct binding to pRb and the induction of 
proteasomal degradation which in turn leads to expression of downstream genes involved in 
cell proliferation. Here we show by Western blotting that pRb is downregulated in 
CRFKE6E7, and both E7 and E6 are responsible of such effect when expressed individually 
(Figure 20A). Consistently, Cyclin A and Cdc2 are upregulated in CRFKE6E7 and CRFKE7, 
while in CRFKE6 Cdc2 but not Cyclin A is overexpressed, suggesting different mechanisms 
of action by E6 and E7 on pRb pathway (Figure 20A). The densitometric mean values 
normalized for β-actin levels from three independent experiments are shown (Fig 20B, C, D). 
Additionally, Real-time qPCR amplifying Cdc2 and cMyc was performed three times in 
technical duplicate, in parallel with GAPDH to allow normalization. As expected, Cdc2 was 
found to be upregulated also at mRNA level, thus strenghtening the biochemical findings 
(Figure 20E).  The cell cycle promoter cMyc was found overexpressed in presence of the 
whole operon E6E7 in repeated experiments, but the specific contribution to its upregulation 
by E6 and E7 individually could not be fully clarified, since the results were not perfectly 
reproducible (data not shown). 
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Figure 20 
FcaPV2 oncogenes impair the pRb pathway. (A) Representative Western blotting showing dowregulation of 
pRb and upregulation of its downstream gene Cdc2 in cells expressing E6, E7 and E6E7; Cycline A is 
upregulated upon E7 expression but not in E6 expressing cells. (B), (C), (D) Mean densitometric values 
normalized to β-actin and SD from three independent experiments for pRb, Cycline A and Cdc2. (E) Real-time 
qPCR data from three independent experiments showing Cdc2 mRNA upregulation in CRFKE6, CRFKE7 and 
CRFKE6E7 compared to CRFKpCEFL.  (*p<0,05, **p<0,01).  
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4.7 FcaPV2 E6 and E7 bind to feline p53 
E6 proteins from alpha HR and several beta cutaneous HPVs are able to bind p53 
protein directing it to proteasome and triggering its degradation. To check whether FcaPV2 
E6 and E7 (since E7 expression was shown to downregulate p53 as well) were able to bind 
p53, GST-FcaPV2 E6 and GST-FcaPV2 E7 fusion proteins were generated and a GST pull-
down assay was performed. Figure 21A shows that FcaPV2 E6 binds to feline p53 when 
incubated with CRFK cell lysate, as well as HPV16 E6. Since the binding HPV16 E6 with 
human p53 is widely known, the same experiment was performed incubating the fusion 
proteins with human cells lysate (HaCat) as positive control: the obtained results confirmed 
this interaction and showed that FcaPV2 E6 is able to bind also human p53 (Figure 21B). 
Surprisingly, HPV16 E7 and FcaPV2 E7 were shown to bind both human and feline p53 
(Figure 21C, D). The ability of HPV16 E7 to bind p53 has never been reported and 
encourages new studies to unravel unexplored mechanism by which HPV16 may impair p53 
tumor suppressor pathway. Despite strongly suggested by these new unreported results, 
whether the binding by FcaPV2 E7 is directly involved in p53 downregulation remains to be 
established in future studies. 
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4.8 FcaPV2 E7 binds to feline pRb 
E7 proteins from HR alpha and several beta cutaneous HPVs bind pRb protein 
directing it to proteasome and triggering its degradation. To check whether FcaPV2 E7 and 
E6 (since pRb was downregulated upon E6 expression as well) were able to bind pRb, a GST 
pull-down assay was performed. Figure 21C shows that FcaPV2 E7 binds to feline pRb in 
CRFK cell lysate, as well as HPV16 E7. The binding of HPV16 E7 to pRb was also 
performed incubating the fusion proteins with human cells lysate (HaCat) as positive control 
(Figure 21D). However, FcaPV2 E6 and, as expected, HPV16 E6 were not able to bind feline 
nor human pRb, suggesting different mechanisms leading to pRb downregulation by FcaPV2 
E6 and E7 (Figure 21A, B). Further studies will clarify this point. 
 
 
 
 
 
 
 
88 
 
 
 
 
Figure 21 
(continued on the following page) 
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FcaPV2 E6 binds to feline and human p53 but not to pRb, while FcaPV2 E7 binds to feline and human 
pRb and p53. (A) GST pull-down assay showing the binding of FcaPV2 and HPV16 GST-E6 fusion proteins to 
feline p53 but not pRb in CRFK cells. One-tenth of the total cellular extract (60 g) used in the GST pulldown 
assay was loaded on the gel as a control (input). (B) The same experiment on HaCat human cell line performed 
as positive control confirmed the interaction of HPV16 E6 with human p53 and showed the same ability by 
FcaPV2E6. One-tenth of HaCat cellular extract used in the GST pull-down assay was loaded as input. (C) GST 
pull-down assay showing the binding of FcaPV2 and HPV16 GST-E7 fusion proteins to feline pRb and p53 in 
CRFK cells. One-tenth of the total cellular extract (60 g) used in the GST pulldown assay was loaded on the gel 
input. (D) The same experiment on HaCat human cell line performed as positive control confirmed the 
interaction of HPV16 E7 with human pRb and showed the same ability by FcaPV2 E7; interactions of HPV16 
E7 and FcaPV2 E7 with human p53 were detected. One-tenth of HaCat cellular extract used in the GST pull-
down assay was loaded as input. 
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4.9 FcaPV2 prolongs the life-span of HPK 
As in healthy epithelia, where they are committed to terminal differentiation after a 
proliferative stage, cultured human primary keratinocytes (HPK) are intended to senescence 
and cell death after several PD. Whether a PV is oncogenic, it is able to immortalize or 
prolong the life-span of HPKs as observed for human and animal oncogenic PVs. Here we 
show that the life-span of primary cells transduced with FcaPV2 E6E7 (pLXSNE6E7) is 
much longer when compared to control cells (pLXSN trandusced cells), with 11 PD versus 1 
PD, respectively (Table 2). When looking at the effect of the single oncogenes, we found that 
HPKs expressing E7 alone (pLXSNE7) were able to undergo 6 PD, while the cells transduced 
with E6 (pLXSNE6) did not survive the selection. To further investigate E6 transforming 
potential, it was tranduced again in HPKs from a different donor, since cells from the previous 
one were no longer available: these primary cells (pLXSNE6) were succesfully selected and 
showed a delayed senescence phase with respect to control cells and grew until reaching 50% 
of confluence, but they were not able to further replicate (Table 2). The growth curve 
showing the different growth profiles and the morphology of each cell line is shown in Figure 
22. These data indicate that FcaPV2 display transforming properties prolonging the life-span 
of primary cells. Additionally, E7 but not E6 seems to be able to increase the proliferative 
ability of HPK, despite less potently than the whole natural operon E6E7.  
 
 
 
91 
 
 
 
 
Figure 22 
                                (continued on following page) 
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FcaPV2 prolongs the life-span of human primary keratinocytes (HPK). (A) Growth curves of HPK 
transduced with the indicated recombinant retroviruses showing the prolonged life-span and the enhanced 
proliferative ability conferred by FcaPV2 E6E7 and FcaPV2 E7 compared to control cells (pLXSN) (left panel); 
FcaPV2 E6 prolonged the senescence phase but did not affect proliferation rate compared to control cells 
(pLXSN) (right panel). (B) Morphology of HPK transduced with the indicated recombinant retroviruses 20 days 
postransduction. Note the features of cellular senescence in pLXSN and FcaPV2 E6 transduced cells with 
enlarged cytoplasms and intercellular bridges. 
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Retrovirus 
 
Number of PD before senescence from donor: 
1 2 
 
None (empty pLXSN) 
 
pLXSNE6E7 
 
pLXSNE6 
 
pLXSNE7 
 
1 
 
11 
 
- 
 
6 
 
0 
 
NA 
 
0,5 
 
NA 
 
Table 2. Life-span of human primary keratinocytes transduced with empty vector pLXSN or with 
recombinant retroviruses pLXSNE6E7, pLXSNE6 and pLXSNE7 and cultured for several population 
dublings (PD) (-: not succesfully transduced; NA: not assessed). 
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5. DISCUSSION  
PVs are double stranded DNA viruses infecting skin and squamous mucosal epithelia 
of mouth and ano-genital tract, where they are able to cause benign hyperproliferative lesions 
as well as malignant cancer in human and animal species (Campo, 2002). Different cutaneous 
lesions are known to occur in the domestic cat, among these SCCs and precursors such as 
viral plaques and BISCs, mostly affecting old, white coated animals in UV-exposed sites 
(nasal planum, ears, eyelids) (Thomson, 2007). This may suggest a role for chronic sun 
exposure, which is known to be a co-factor in the development of beta HPVs-associated 
cutaneous SCC in humans (Howley and Pfister, 2015). SCCs are the most common cutaneous 
and oral malignant cancer in cats; they are locally invasive, may metastasize and are not 
responsive to the current therapies and surgical excision, thus being often fatal or forcing vets 
to carry out euthanasia (Gross et al., 2005). Molecular investigations throughout the last years 
revealed a frequent and specific association of FcaPV2 DNA with cutaneous SCCs and 
precursors, suggesting that PV infection is involved in the pathogenesis of skin cancer also in 
domestic cat (reviewed in Munday, 2013). As many PVs, FcaPV2 potentially encodes for E6 
and E7, which are considered to be oncogenes for analogy with other skin and mucosal PVs. 
FcaPV2 contains also an ORFs for E2 gene, usually involved in viral genes transcriptional 
regulation and viral replication (Lange et al., 2009; McBride, 2013). However, viral gene 
expression has never been demonstrated within feline skin cancer so far, thus a causative role 
cannot be yet proven. In this work we showed by type-specific PCR that 100% of feline SCCs 
(including one oral sample) were positive for FcaPV2 DNA versus 40% of normal skins and 
0/2 non SCC skin lesions, in accordance with previous studies showing similarly higher rate 
of association in SCCs. Additionally, this widely reported FcaPV2 inert infection in clinically 
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healthy animals is very common also for human and other animal PVs: indeed, PVs may 
undergo latent infection without clinical manifestations until other co-factors, such as the 
aforementioned UV-exposure, interplay with the virus to trigger lesions development and/or 
malignant transformation (Thomson et al., 2015; Munday, 2013; Doorbar, 2005; Antonsson et 
al., 2000; Antonsson et al., 2002). Most importantly, FcaPV2 was found to be 
transcriptionally active in 89% of our SCCs samples but only in 20% of normal skin, thus 
corroborating the hypothesis of a carcinogenic role of the virus. Indeed, E2 expression suggest 
transcriptional and replicative activity by FcaPV2 in vivo. Furthermore, the expression of the 
putative oncogenes E6 and E7 strongly suggest that the virus may display transforming 
activity in the infected epithelia contributing to cancer development (Stoler et al., 1992). 
Unfortunately, we could not assess histopathological diagnosis of normal skin samples, thus 
the hypothesis that those found positive for FcaPV2 mRNA may be dysplastic or not fully 
healthy cannot be ruled out. Another possible explanation may be that the virus could have 
infected a subset of cells sufficient in supporting viral cycle but not in triggering development 
of macro/microscopically detectable neoplastic lesion (Doorbar et al., 2005). 
 A significant subset (about 20%) of oral SCC in humans is caused by HR alpha HPVs 
(reviewed in Howley, 2013). In domestic cat, FcaPV1 DNA has been found to be associated 
with oral papillomas and FcaPV4 DNA with an inflammatory disease of the oral cavity, but 
not with oral SCCs (Dunowska et al., 2014; Munday and French, 2015). Although referred to 
only one sample, FcaPV2 gene expression in the oral SCC analyzed in this study may suggest 
a mixed tropism of this virus, both for skin and oral squamous epithelia, and a possible role in 
oral SCC development.  
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Once the expression of viral putative oncogenes was demonstrated in skin tumours in 
vivo, we aimed at establishing an in vitro model, in order to molecularly characterize the 
possible transforming properties of FcaPV2, and the tumor suppressors p53 and pRb 
pathways were investigated, since they are frequently impaired in PVs induced cancer (for 
review see Nguyen et al., 2014). 
Normally present at low levels in cells, p53 tumour suppressor is a transcription factor 
coordinating the cellular response to genotoxic or citotoxic stress such as UV-induced DNA 
damage. UV irradiation leads to an increasing in p53 protein levels and activation via post-
translational modifications, resulting in increased expression of cell cycle inhibitors such as 
p21 and/or pro-apoptotic genes including Bax, so that cells are committed to DNA repair or 
apoptosis in order to avoid transmission of oncogenic mutations to doughter cells (Murray-
Zmijevski et al., 2008). The E6 oncoproteins have been implicated in the potential 
carcinogenic activities of beta cutaneous HPVs, mostly through interfering with those 
processes, thus allowing cells with UV-triggered mutations to survive and progress to cancer. 
Differently from E6 of alpha HR HPVs that binds to p53 leading it to proteasomal 
degradation and loss of tumour suppressor activity (Scheffner et al., 1990), most of E6 
proteins from beta cutaneous HPVs are known to impair p53 function through different 
mechanisms (reviewed in Howley et al., 2015). The only exception known so far is the beta 3 
type HPV49, whose E6 binds to and degrades p53, and HPV76 E6, which is associated with 
lower p53 protein levels through unknown mechanisms (Cornet et al., 2012; White et al., 
2014). Here, we show by GST pull-down assay that FcaPV2 E6 binds to feline p53 protein 
which results to be downregulated, suggesting that this oncogene behaves similarly to those 
from alpha HR HPVs and beta HPV49 and 76. Surprisingly, p53 was found to be 
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downregulated also upon E7 expression (CRFKE6E7 and CRFKE7) and to bind E7 as well. 
Whether the physical interaction is involved in p53 downregulation by E7 has to be 
investigated in further studies. Additionally, when investigating p53 gene expression through 
qPCR, we found lower p53 mRNA levels in E7 expressing cells. To the best of our 
knowledge, no PVs E7 has been reported to downregulate p53 gene expression so far. Several 
works show that suppression of HPV16 E7 expression leads to restoring of p53 protein but 
not at mRNA level and E7 from beta cutaneous HPV38 is known to selectively inhibit 
expression of p53 downstream genes (Guo et al., 2011; Lee et al., 2011; Kim et al., 2012; 
Kim et al., 2013., Saidj et al., 2013); all these findings suggest that human and animal PVs 
may have evolved different mechanisms to reduntantly impair p53 pathway by E7 other than 
by E6. Consistently with low p53 basal levels, when subjected to Western blotting after UVB 
irradiation, feline epithelial cells expressing the FcaPV2 oncogenes did not show significant 
p53 accumulation and, as a consequence, the cell cycle inhibitor p21 was not upregulated. The 
alpha HR HPV16 and 18 E6 have been shown to inhibit p53 dependent-p21 accumulation and 
p21 was not responsive to UVB irradiation in cells expressing beta types HPV38, 49 and 76 
due to p53 inactivation, suggesting that FcaPV2 E6 shares common mechanisms with 
mucosal and cutaneous HPVs to impair p21-dependent cell cycle arrest (Cornet et al., 2012; 
White et al., 2014). Additionally, FcaPV2 oncogenes were found to be able to counteract 
UVB induced apoptosis at the same experimental conditions by Western blotting for different 
apoptotic markers: indeed, Caspase3, a downstream effector of intrinsic apoptosis activated 
by proteolytic cleavage (for review see Shalini et al., 2015), was found to be cleaved only in 
control cells but not in cells expressing E6E7, E6 and E7 after UVB treatment; consistently 
Bax, a pro-apoptotic protein involved in the formation of the mythocondrial pores which 
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allows the formation of the apoptosome (Narita et al., 1998), was not accumulated after UVB 
irradiation in cells expressing FcaPV2 oncogenes, particularly upon E6 expression. Since Bax 
gene is under the transcriptional control of p53 and is upstream to Caspase3 in the apoptotic 
intrinsic pathway (Miyashita et al., 1994), the inhibition of apoptosis by FcaPV2 may be, at 
least in part, dependent on the impairment of p53 pathway by E6 and E7. However, 
suppression of E6 and E7 expression increases Caspase3 cleavage with a p53 independent 
manner in chemically-induced apoptosis in cells expressing HPV16 (Kim et al., 2013; Magal 
et al., 1998). Furthermore, anti-apoptotic activity of E6 from several cutaneous beta types has 
been shown to be uncoupled from p53 transcriptional activity and to be exerted also in p53 
null cell lines after UVB exposure, thus further investigations are needed to clarify whether 
inhibition of apoptosis by FcaPV2 is mechanistically p53-dependent (Jackson and Storey, 
2000; Giampieri et al., 2004). Another mechanism by which E6 proteins from a series of 
cutaneous HPVs such as HPV5, 8, 20, 22, 38, 76, 92 and 96 may counteract UVB-induced 
apoptosis is the degradation of pro-apoptotic protein Bak which, synergistically with Bax, 
normally contributes to the release of mythocondrial pro-apoptotic factors (Jackson et al., 
2000; Jackson and Storey, 2000; Underbrink et al., 2008); several studies on different models 
show that, regardless of whether Bak degradation is constitutive or induced by UVB, it  never 
accumulates in cells expressing cutaneous and mucosal HPVs E6, depending on proteasomal 
degradation (reviewed in Howley and Pfister, 2015). Additionally, E6 and E7 from alpha HR 
HPVs have been found to degrade Bak and impair apoptosis induced by different cellular 
stresses including UV (Liu et al., 2008; Du et al., 2004). Here, we showed that basal levels of 
Bak are variable among the different cell lines, but it does not accumulate in CRFK cells 
expressing FcaPV2 oncogenes after UVB treatment, suggesting that FcaPV2 shares similar 
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biological properties with oncogenic HPVs in impairing Bak, thus preventing UVB-induced 
apoptosis. Much more controversies exist about the regulation of anti-apoptotic members of 
Bcl-2 protein family by PVs oncogenes, among these Bcl-Xl. In non apoptotic cells, Bcl-Xl 
binds to Bak and blocks its heterodimerization with Bax (Sattler et al., 1997), thus inhibiting 
the mythocondrial apoptotic cascade; normally, following apoptotic stimuli such as UVB 
irradiation, Bcl-Xl is downregulated (Michels et al., 2013; Galluzzi et al., 2011). Whilst Bcl-
Xl responsiveness to UVB irradiation has never been found to be affected, at least at protein 
level, by expression of beta HPVs E6 proteins, several studies indicate that suppression of 
HPV18 E6 and, less commonly, E7 expression leads to Bcl-Xl decreasing thus triggering 
apoptosis (Strujiki et al., 2008; Li et al., 2015; Ham et al., 2014; Underbrink et al., 2008). Our 
findings demonstrate by qPCR that Bcl-Xl gene is downregulated in irradiated control cells 
but, interestingly, this phenomenon is inhibited in presence of FcaPV2 oncogenes, with E6 
being the major responsible of such biological effect, indicating that the virus counteracts also 
Bcl-Xl pathway to inhibit cell death as HPV18. Bcl-Xl is, at least in part, under transcriptional 
control of p53, thus UVB-induced Bcl-Xl downregulation may be inhibited along with the 
impairment of p53 pathway upon FcaPv2 oncogenes expression (Galluzzi et al., 2011). Taken 
together, all these findings strongly suggest that FcaPV2 acts synergistically with UV light in 
the development of feline SCC, as already known for human counterpart. 
Along with p53, the pRb pathway is commonly impaired in PVs induced cancer. The 
tumour suppressor pRb is a transcriptional repressor that binds to and block E2F transcription 
factor, inhibiting the activation of genes involved in cell cycle progression and cell 
proliferation (for review see Frolov et al., 2004). E7 from HR HPVs binds to pRb protein 
through the pRb binding domain LXCXE directing the cellular tumour suppressor through 
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proteasomal degradation, whilst cutaneous beta HPVs E7 proteins enhance the 
phosphorylation of pRb: both mechanisms lead to the release of E2F, which in turn activates 
the expression of pro-proliferative genes Ciclyne A, Cdc2 and cMyc (Dyson et al., 1992; Huh 
et al., 2007; Zerfass et al., 1995; Cornet et al., 2012). In our model, Western blotting analysis 
showed lower pRb levels in cells expressing E6E7 and E7, but surprisingly we found pRb 
downregulation also when E6 was expressed individually.  Consistently, both Western 
blotting and qPCR showed higher Cdc2 expression in CRFKE6E7, CRFKE7 and CRFKE6 
compared to control cells. However, Cycline A was upregulated in E7 but not E6 expressing 
cells. Furthermore FcaPV2 E7 contains the canonical pRb binding domain LXCXE (Lange et 
al., 2009) and GST pull-down assay demonstrated that, as expected, E7 but not E6 was able to 
bind feline pRb, suggesting that E6 may act on pRb pathway with differents mechanisms with 
respect to E7, possibly affecting Cdc2 but not Cyclin A expression. Additionally, studies 
conducted on cutaneous HPV14 and 22, indicate that lower pRb levels does not necessary 
result in genes upregulation, indicating that additional events may be required to deregulate 
pRb downstream genes expression (Cornet et al., 2012). Similarly, qPCR showed higher 
levels of cMyc mRNA in presence of FcaPV2 E6E7 operon, but repeated experiments did not 
yield clearly reproducible results on cells expressing E6 and E7 individually, thus the exact 
contribution of each of the two oncogenes should be investigated by further studies. Previous 
studies reported pRb downregulation and Cyclin A overexpression in feline SCC in vivo 
(Munday and Aberdein, 2012; Murakami et al., 2000), thus the results obtained in our 
functional model strongly suggest a role of FcaPV2 in corrupting pRb pathway and 
contributing to SCC development; however, whilst FcaPVE7 seems to behave like HR HPVs 
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E7, further studies are required to understand the molecular mechanism by which E6 may 
differently impair pRb pathway.  
To further characterize the transforming properties of FcaPV2 oncogenes, an in vitro 
immortalization assay was performed. Oncogenic HPVs are able to immortalize or prolong 
the life-span of HPK (Cornet et al., 2012). We observed that HPK transduced with 
recombinant retroviruses expressing E6E7 showed a longer life-span, being able to undergo 
more PD and to survive in culture for many additional days when compared to control cells, 
confirming the transforming potential of FcaPV2. When expressed individually, E6 was 
found only to be able to prolong the senescence phase without affecting the proliferation 
ability of HPK, whilst E7 enhanced the number of PD but less efficiently than E6E7, 
suggesting that they make different contributions to the transforming process and must act 
synergistically to display the full carcinogenic potential of FcaPV2. In veterinary oncology, 
similar findings were reported for the CRPV, where E7 was shown to prolong alone and in 
combination with E6 the life-span of HPK, suggesting that this is a reliable assay to analyze 
the transforming properties of E6 and E7 oncogenes of animal PVs (Ganzenmueller et al., 
2008). 
In summary, our study demonstrates for the first time a possible causative role of 
FcaPV2 in vitro. We showed viral gene expression in vivo in tumour samples and we 
established the first in vitro model in order to characterize the transforming properties of 
FcaPV2 E6 and E7 oncogenes. The p53 and pRb pathways classically corrupted in PV-
induced cancer were found to be impaired by E6 and E7, respectively, and new possible 
cross-acting mechanisms on the reciprocal pathway were identified. Furthermore, the two 
oncogenes were able to impair UVB-induced cell cycle arrest and apoptosis, strengthening the 
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hypothesis of sun exposure as a co-factor in viral-triggered skin carcinogenesis in the 
domestic cat, and to prolong the life-span of primary cells, confirming definitively the 
transforming properties of FcaPV2. 
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6. FUTURE PROSPECTS 
Skin tumours of domestic cat are of considerable interest in veterinary medicine, since 
they are not responsive to current therapies and are often lethal. Unraveling molecular 
pathways whose alterations are at the basis of feline skin cancer may open a new field of 
inquiry addressed to the formulation of vaccination principals for the prevention of these 
severe tumors of cats, as it has recently happened with HPV induced cervical cancer in 
women, and/or to the identification of molecular targets for a possible therapeutical approach. 
Additionally, they show high similarity with the human counterpart. Thus, feline SCC is 
considered a new model for the study of spontaneous SCC human as well. 
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